[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSEJm-j6aHTE8bH4NF7cIxiOwWv0La_fmmm43DI9w6tk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"The Netherlands Cancer Institute",[4],227,false,77,32,97124,99,103,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Breast Cancer",35,{"name":18,"count":19},"Prostate Cancer",11,{"name":21,"count":22},"Colorectal Cancer",7,{"name":24,"count":22},"Head and Neck Cancer",{"name":26,"count":27},"Carcinoma, Non-Small-Cell Lung",6,{"name":29,"count":27},"Ovarian Cancer",{"name":31,"count":32},"Melanoma",5,{"name":34,"count":32},"NSCLC",[36,41,46,51,56,61,64,69,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT01996267","Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","2018-12","PTC+Pertuzumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04159818","Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","2022-12-15","Nivolumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT01646034","High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer","2023-01","carboplatin, thiotepa, and cyclophosphamide",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT01057069","Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","2023-06","Carboplatin and Paclitaxel",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04192253","Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)","2024-01-01","Paclitaxel and Carboplatin",{"nctId":62,"briefTitle":63,"date":59,"intervention":60},"NCT04161664","Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT04949113","Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","2024-01-12","Neoadjuvant ipilimumab + nivolumab",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT01898117","Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer","2024-04-01","Carbo\u002Fcyclo",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT02810743","Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","2024-07-18","ddAC-CP-Olaparib",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05401786","Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC","2024-11-15","Ipilimumab",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,120,229,277,311,336,354,377,395,424,442,460,487,509,527,552,570,593,611,629,652,670,702,720,748,778,796,1005,1082,1165,1222,1262,1321,1374,1408,1465,1487,1509,1543,1565,1599,1630,1656,1689,1711,1733,1761,1783,1809,1827,1852,1870,1888,1906,1924,1942,1967,1994,2012,2030,2048,2066,2090,2116,2134,2152,2170,2197,2215,2233,2251,2269,2287,2305,2323,2341,2359,2377,2395,2413,2431,2449,2467,2485,2503,2521,2539,2557,2575,2593,2611,2629,2647,2665,2702,2720,2738,2756,2780,2807,2831,2857,2879,2917,2942,2965,2983,3008,3026,3050,3068,3086,3104,3122,3163,3200,3222,3256,3278,3296,3320,3344,3368,3386,3404,3429,3454,3477,3501,3519,3544,3565,3583,3601,3619,3645,3663,3681,3699,3725,3750,3768,3786,3812,3836,3860,3884,3907,3931,3955,3973,3998,4016,4041,4059,4082,4109,4127,4145,4172,4190,4216,4240,4264,4298,4323,4347,4370],{"intervention":93,"totalTrials":94,"cells":95},"Sildenafil",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":118},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":112},[107],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT06875258","PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)","RECRUITING",[89],"2027-01-01","2024-01-15",198,[116],"Erectile Dysfunction Following Radical Prostatectomy",[93],{"trials":119,"activeCount":98},[],{"intervention":121,"totalTrials":122,"cells":123},"Cisplatin",8,{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":164,"PHASE3":197,"PHASE4":225,"NA":227},{"trials":125,"activeCount":98},[],{"trials":127,"activeCount":98},[128,139,150],{"nctId":129,"briefTitle":130,"status":131,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT01933568","Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.","COMPLETED",[86],"2018-11-11","2013-02-28",15,[137],"Inoperable Locally Advanced Non Small Cell Lung Cancer",[121],{"nctId":140,"briefTitle":141,"status":131,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":148},"NCT01562210","Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC",[86],"2019-05","2020-03-13","2012-04",28,[34],[149,121],"Olaparib",{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT04287894","Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and\u002For Resection in the Treatment","TERMINATED",[86],"2024-11-04","2018-12-28",18,[159],"Stage III NSCLC",[161,162,163,121],"Durvalumab","Tremelimumab","Pemetrexed",{"trials":165,"activeCount":94,"soonestReadout":44},[166,179,189],{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT02499367","Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients","UNKNOWN",[87],"2023-12","2025-08","2015-08",84,[15],[45,177,178,121],"Low dose doxorubicin","Cyclophosphamide",{"nctId":180,"briefTitle":181,"status":182,"phases":183,"primaryCompletion":184,"completion":184,"start":184,"enrollment":98,"conditions":185,"interventions":187},"NCT02947113","Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC","WITHDRAWN",[87],"2017-11",[186],"Non-Small Cell Lung Cancer",[121,163,188],"Etoposide",{"nctId":42,"briefTitle":43,"status":110,"phases":190,"primaryCompletion":44,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},[87],"2026-12-15","2020-02-21",52,[195],"Metastatic Breast Cancer",[45,121,177],{"trials":198,"activeCount":94,"soonestReadout":219},[199,214],{"nctId":200,"briefTitle":201,"status":169,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":209},"NCT02743923","Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer",[88],"2021-09-19","2024-04","2016-04",203,[208],"Carcinoma, Non-Small Cell Lung",[210,211,212,163,213],"carboplatin","paclitaxel","Bevacizumab","cisplatin",{"nctId":215,"briefTitle":216,"status":217,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":224},"NCT03772028","Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","ACTIVE_NOT_RECRUITING",[88],"2028-04-01","2028-12-01","2020-01-01",538,[29],[213],{"trials":226,"activeCount":98},[],{"trials":228,"activeCount":98},[],{"intervention":212,"totalTrials":230,"cells":231},3,{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":249,"PHASE4":273,"NA":275},{"trials":233,"activeCount":98},[],{"trials":235,"activeCount":98},[],{"trials":237,"activeCount":94,"soonestReadout":242},[238],{"nctId":239,"briefTitle":240,"status":217,"phases":241,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT04017455","Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)",[87],"2025-08-31","2019-10-22",38,[246],"Rectal Cancer",[248,212],"Atezolizumab",{"trials":250,"activeCount":94,"soonestReadout":255},[251,269],{"nctId":252,"briefTitle":253,"status":110,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":267},"NCT06888817","Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases",[88],"2028-07","2030-07","2025-06-19",408,[260,261,262,263,264,265,266],"Radiation Necrosis","High Grade Glioma (III or IV)","Brain Metastasases","Radiation Toxicity","Radiation Effect","Radiation Injury","Radiation Injuries",[212,268],"Dexamethasone",{"nctId":200,"briefTitle":201,"status":169,"phases":270,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":271,"interventions":272},[88],[208],[210,211,212,163,213],{"trials":274,"activeCount":98},[],{"trials":276,"activeCount":98},[],{"intervention":278,"totalTrials":279,"cells":280},"chemotherapy",2,{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":298,"PHASE4":307,"NA":309},{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":98},[],{"trials":286,"activeCount":98},[287],{"nctId":288,"briefTitle":289,"status":131,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":9,"conditions":294,"interventions":296},"NCT01211275","Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma",[86,87],"2012-11-13","2013-05-06","2009-05-22",[295],"Malignant Pleural Mesothelioma",[297,278],"axitinib",{"trials":299,"activeCount":94,"soonestReadout":49},[300],{"nctId":47,"briefTitle":48,"status":217,"phases":301,"primaryCompletion":49,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":306},[88],"2026-10","2014-09",74,[15],[50,278],{"trials":308,"activeCount":98},[],{"trials":310,"activeCount":98},[],{"intervention":312,"totalTrials":94,"cells":313},"Transtympanic sodium thiosulphate (STS) 0.1M\u002F0,5% hyaluronate",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":332,"NA":334},{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":98},[],{"trials":319,"activeCount":98},[],{"trials":321,"activeCount":94,"soonestReadout":326},[322],{"nctId":323,"briefTitle":324,"status":110,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":331},"NCT07281508","Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial",[88],"2030-03-23","2025-08-14",100,[330],"Cisplatin-related Hearing Loss",[312],{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":98},[],{"intervention":50,"totalTrials":94,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":344,"PHASE4":350,"NA":352},{"trials":339,"activeCount":98},[],{"trials":341,"activeCount":98},[],{"trials":343,"activeCount":98},[],{"trials":345,"activeCount":94,"soonestReadout":49},[346],{"nctId":47,"briefTitle":48,"status":217,"phases":347,"primaryCompletion":49,"completion":302,"start":303,"enrollment":304,"conditions":348,"interventions":349},[88],[15],[50,278],{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":98},[],{"intervention":40,"totalTrials":94,"cells":355},{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":373,"NA":375},{"trials":357,"activeCount":98},[],{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":94,"soonestReadout":39},[364],{"nctId":37,"briefTitle":38,"status":217,"phases":365,"primaryCompletion":39,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":371},[88],"2030-12","2013-12",437,[15,370],"HER2 Positive",[40,372],"FEC-T+Pertuzumab",{"trials":374,"activeCount":98},[],{"trials":376,"activeCount":98},[],{"intervention":372,"totalTrials":94,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":391,"NA":393},{"trials":380,"activeCount":98},[],{"trials":382,"activeCount":98},[],{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":94,"soonestReadout":39},[387],{"nctId":37,"briefTitle":38,"status":217,"phases":388,"primaryCompletion":39,"completion":366,"start":367,"enrollment":368,"conditions":389,"interventions":390},[88],[15,370],[40,372],{"trials":392,"activeCount":98},[],{"trials":394,"activeCount":98},[],{"intervention":396,"totalTrials":94,"cells":397},"botensilimab",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":420,"NA":422},{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":94,"soonestReadout":410},[406],{"nctId":407,"briefTitle":408,"status":110,"phases":409,"primaryCompletion":410,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":417},"NCT06279130","Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations",[87,88],"2029-01-29","2034-01-29","2024-01-29",133,[415,416],"Resectable MMR-deficient Solid Tumors","Resectable MMR-proficient Solid Tumors",[396,418,419],"balstilimab","FLOT",{"trials":421,"activeCount":98},[],{"trials":423,"activeCount":98},[],{"intervention":418,"totalTrials":94,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":438,"NA":440},{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":94,"soonestReadout":410},[434],{"nctId":407,"briefTitle":408,"status":110,"phases":435,"primaryCompletion":410,"completion":411,"start":412,"enrollment":413,"conditions":436,"interventions":437},[87,88],[415,416],[396,418,419],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"intervention":419,"totalTrials":94,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":456,"NA":458},{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":94,"soonestReadout":410},[452],{"nctId":407,"briefTitle":408,"status":110,"phases":453,"primaryCompletion":410,"completion":411,"start":412,"enrollment":413,"conditions":454,"interventions":455},[87,88],[415,416],[396,418,419],{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":98},[],{"intervention":461,"totalTrials":94,"cells":462},"Hyperthermic Intraperitoneal Chemotherapy",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":483,"NA":485},{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":98},[],{"trials":470,"activeCount":94,"soonestReadout":475},[471],{"nctId":472,"briefTitle":473,"status":217,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":482},"NCT03348150","Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.",[88],"2025-09-17","2027-10-01","2017-10-01",102,[480,481],"Stomach Neoplasm","Peritoneal Carcinomatosis",[461],{"trials":484,"activeCount":98},[],{"trials":486,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":505,"NA":507},{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":98},[],{"trials":496,"activeCount":94,"soonestReadout":77},[497],{"nctId":75,"briefTitle":76,"status":217,"phases":498,"primaryCompletion":77,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":503},[88],"2033-12-01","2017-01-25",174,[15],[78,504],"ddAC-mini CTC",{"trials":506,"activeCount":98},[],{"trials":508,"activeCount":98},[],{"intervention":504,"totalTrials":94,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":523,"NA":525},{"trials":512,"activeCount":98},[],{"trials":514,"activeCount":98},[],{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":94,"soonestReadout":77},[519],{"nctId":75,"briefTitle":76,"status":217,"phases":520,"primaryCompletion":77,"completion":499,"start":500,"enrollment":501,"conditions":521,"interventions":522},[88],[15],[78,504],{"trials":524,"activeCount":98},[],{"trials":526,"activeCount":98},[],{"intervention":528,"totalTrials":94,"cells":529},"Sonazoid",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":548,"NA":550},{"trials":531,"activeCount":98},[],{"trials":533,"activeCount":98},[],{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":94,"soonestReadout":542},[538],{"nctId":539,"briefTitle":540,"status":110,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":547},"NCT07310758","Contrast-enhanced Ultrasound for Sentinel Node Detection",[87,88],"2026-09-18","2025-09-18",91,[31,15,546],"Head & Neck Cancer",[528],{"trials":549,"activeCount":98},[],{"trials":551,"activeCount":98},[],{"intervention":268,"totalTrials":94,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":566,"NA":568},{"trials":555,"activeCount":98},[],{"trials":557,"activeCount":98},[],{"trials":559,"activeCount":98},[],{"trials":561,"activeCount":94,"soonestReadout":255},[562],{"nctId":252,"briefTitle":253,"status":110,"phases":563,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":564,"interventions":565},[88],[260,261,262,263,264,265,266],[212,268],{"trials":567,"activeCount":98},[],{"trials":569,"activeCount":98},[],{"intervention":55,"totalTrials":94,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":589,"NA":591},{"trials":573,"activeCount":98},[],{"trials":575,"activeCount":98},[],{"trials":577,"activeCount":98},[],{"trials":579,"activeCount":94,"soonestReadout":54},[580],{"nctId":52,"briefTitle":53,"status":217,"phases":581,"primaryCompletion":54,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":586},[87,88],"2029-12","2010-01",310,[15],[55,587,588],"Doxorubicin, cyclophosphamide","Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide",{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[],{"intervention":587,"totalTrials":94,"cells":594},{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":607,"NA":609},{"trials":596,"activeCount":98},[],{"trials":598,"activeCount":98},[],{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":94,"soonestReadout":54},[603],{"nctId":52,"briefTitle":53,"status":217,"phases":604,"primaryCompletion":54,"completion":582,"start":583,"enrollment":584,"conditions":605,"interventions":606},[87,88],[15],[55,587,588],{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[],{"intervention":588,"totalTrials":94,"cells":612},{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":619,"PHASE4":625,"NA":627},{"trials":614,"activeCount":98},[],{"trials":616,"activeCount":98},[],{"trials":618,"activeCount":98},[],{"trials":620,"activeCount":94,"soonestReadout":54},[621],{"nctId":52,"briefTitle":53,"status":217,"phases":622,"primaryCompletion":54,"completion":582,"start":583,"enrollment":584,"conditions":623,"interventions":624},[87,88],[15],[55,587,588],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"intervention":68,"totalTrials":94,"cells":630},{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":637,"PHASE4":648,"NA":650},{"trials":632,"activeCount":98},[],{"trials":634,"activeCount":98},[],{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":94,"soonestReadout":67},[639],{"nctId":65,"briefTitle":66,"status":217,"phases":640,"primaryCompletion":67,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":646},[88],"2028-12-19","2021-07-08",423,[645],"Malignant Melanoma Stage III",[68,647],"Adjuvant nivolumab",{"trials":649,"activeCount":98},[],{"trials":651,"activeCount":98},[],{"intervention":647,"totalTrials":94,"cells":653},{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":666,"NA":668},{"trials":655,"activeCount":98},[],{"trials":657,"activeCount":98},[],{"trials":659,"activeCount":98},[],{"trials":661,"activeCount":94,"soonestReadout":67},[662],{"nctId":65,"briefTitle":66,"status":217,"phases":663,"primaryCompletion":67,"completion":641,"start":642,"enrollment":643,"conditions":664,"interventions":665},[88],[645],[68,647],{"trials":667,"activeCount":98},[],{"trials":669,"activeCount":98},[],{"intervention":671,"totalTrials":94,"cells":672},"Standard of care plus pembrolizumab",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":698,"NA":700},{"trials":674,"activeCount":98},[],{"trials":676,"activeCount":98},[],{"trials":678,"activeCount":98},[],{"trials":680,"activeCount":94,"soonestReadout":686},[681],{"nctId":682,"briefTitle":683,"status":684,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":696},"NCT07486687","Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","NOT_YET_RECRUITING",[88],"2032-04","2036-04","2026-04",1000,[691,692,693,694,695],"Triple Negative Breast Cancer (TNBC), Early Setting","Early Stage Triple-Negative Breast Carcinoma","Triple -Negative Breast Cancer","Breast Cancer Stage II","Breast Cancer Stage III",[671,697],"Standard of care",{"trials":699,"activeCount":98},[],{"trials":701,"activeCount":98},[],{"intervention":697,"totalTrials":94,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":716,"NA":718},{"trials":705,"activeCount":98},[],{"trials":707,"activeCount":98},[],{"trials":709,"activeCount":98},[],{"trials":711,"activeCount":94,"soonestReadout":686},[712],{"nctId":682,"briefTitle":683,"status":684,"phases":713,"primaryCompletion":686,"completion":687,"start":688,"enrollment":689,"conditions":714,"interventions":715},[88],[691,692,693,694,695],[671,697],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"intervention":721,"totalTrials":94,"cells":722},"Somatostatin analog",{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":729,"PHASE4":744,"NA":746},{"trials":724,"activeCount":98},[],{"trials":726,"activeCount":98},[],{"trials":728,"activeCount":98},[],{"trials":730,"activeCount":94,"soonestReadout":112},[731],{"nctId":732,"briefTitle":733,"status":110,"phases":734,"primaryCompletion":112,"completion":735,"start":736,"enrollment":737,"conditions":738,"interventions":743},"NCT06855095","Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial",[87,88],"2027-03-01","2024-06-25",39,[739,740,741,742],"Neuroendocrine Tumors","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Neoplasm",[721],{"trials":745,"activeCount":98},[],{"trials":747,"activeCount":98},[],{"intervention":749,"totalTrials":94,"cells":750},"Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":774,"NA":776},{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":94,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":110,"phases":762,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":772},"NCT06857773","Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy",[88],"2030-01","2035-01","2024-11-21",306,[768,769,770,771],"Colorectal Neoplasms","Floxuridine","Liver Metastases","Vascular Access Device",[749,773],"Systemic therapy",{"trials":775,"activeCount":98},[],{"trials":777,"activeCount":98},[],{"intervention":773,"totalTrials":94,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":792,"NA":794},{"trials":781,"activeCount":98},[],{"trials":783,"activeCount":98},[],{"trials":785,"activeCount":98},[],{"trials":787,"activeCount":94,"soonestReadout":763},[788],{"nctId":760,"briefTitle":761,"status":110,"phases":789,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":790,"interventions":791},[88],[768,769,770,771],[749,773],{"trials":793,"activeCount":98},[],{"trials":795,"activeCount":98},[],{"intervention":45,"totalTrials":135,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":822,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":799,"activeCount":98},[],{"trials":801,"activeCount":98},[802,813],{"nctId":803,"briefTitle":804,"status":131,"phases":805,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":812},"NCT03387761","Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy",[86],"2021-07-19","2025-01-07","2018-01-15",54,[811],"Urothelial Carcinoma",[83,45],{"nctId":814,"briefTitle":815,"status":131,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":135,"conditions":820,"interventions":821},"NCT04871594","Pre-operative Immunotherapy in Stage II-III Urothelial Cancer",[86],"2023-06-02","2024-12-30","2021-08-23",[811],[45],{"trials":823,"activeCount":22,"soonestReadout":44},[824,834,838,850,864,868,890,903,914,922,932,942,951],{"nctId":825,"briefTitle":826,"status":169,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":833},"NCT02977052","Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab",[87],"2020-01-03","2025-06","2016-11-24",186,[645],[83,45],{"nctId":167,"briefTitle":168,"status":169,"phases":835,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":836,"interventions":837},[87],[15],[45,177,178,121],{"nctId":839,"briefTitle":840,"status":131,"phases":841,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":849},"NCT03003637","ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma",[86,87],"2019-10-12","2021-02-12","2017-02-28",33,[847,848],"Immunotherapy","Head and Neck Neoplasms",[45,83],{"nctId":851,"briefTitle":852,"status":110,"phases":853,"primaryCompletion":854,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":862},"NCT06823479","Towards Cure Via Only Ultra-short ICB in CSCC",[87],"2029-02","2025-05-14",41,[858,859,860,861],"Cutaneous Squamous Cell Carcinoma (CSCC)","Cutaneous Squamous Cell Cancer","Cutaneous Squamous Cell Carcinoma of the Head and Neck","Cutaneous Squamous Cell Carcinoma",[45,863],"Ipilumimab",{"nctId":42,"briefTitle":43,"status":110,"phases":865,"primaryCompletion":44,"completion":191,"start":192,"enrollment":193,"conditions":866,"interventions":867},[87],[195],[45,121,177],{"nctId":869,"briefTitle":870,"status":110,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":888},"NCT06237920","Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab",[87],"2026-07-01","2028-08-01","2024-02-19",90,[877,878,879,880,881,882,883,884,885,886,887],"Urologic Neoplasms","Urogenital Neoplasms","Neoplasms by Site","Neoplasms","Female Urogenital Diseases","Female Urogenital Diseases and Pregnancy Complications","Urogenital Diseases","Urinary Bladder Diseases","Male Urogenital Diseases","Urinary Bladder Neoplasm","Antineoplastics Toxicity",[45,889],"Relatlimab",{"nctId":891,"briefTitle":892,"status":110,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT03026140","Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer",[87],"2032-03-01","2017-03-29",353,[898],"Colon Carcinoma",[45,83,900,901,902],"Celecoxib 200mg","BMS-986253","BMS-986016",{"nctId":904,"briefTitle":905,"status":131,"phases":906,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":912},"NCT04133948","Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma",[86,87],"2022-01-11","2024-11-26","2020-01-07",44,[645],[913,45,83],"Domatinostat",{"nctId":915,"briefTitle":916,"status":131,"phases":917,"primaryCompletion":807,"completion":807,"start":918,"enrollment":919,"conditions":920,"interventions":921},"NCT04620200","Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery",[87],"2020-08-11",50,[861],[45,83],{"nctId":923,"briefTitle":924,"status":110,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":931},"NCT06240143","Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma",[86,87],"2029-07","2034-03","2024-03-08",96,[31],[83,45,45],{"nctId":933,"briefTitle":934,"status":110,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":941},"NCT03815890","Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO",[87],"2031-01-01","2033-01-01","2019-10-04",80,[15],[45,83,83],{"nctId":943,"briefTitle":944,"status":131,"phases":945,"primaryCompletion":946,"completion":946,"start":947,"enrollment":845,"conditions":948,"interventions":949},"NCT02497508","Nivolumab in Patients With Recurrent Malignant Mesothelioma",[87],"2017-07","2015-07",[295],[950],"nivolumab",{"nctId":952,"briefTitle":953,"status":110,"phases":954,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":964},"NCT02925234","The Drug Rediscovery Protocol (DRUP Trial)",[87],"2027-09","2027-12","2016-08",1550,[960,961,962,963],"Cancer","Tumors","Neoplasm","Neoplasia",[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],"Panitumumab","Dabrafenib","Nilotinib","Trametinib","Erlotinib","Trastuzumab and Pertuzumab","Vemurafenib and Cobimetinib","Vismodegib","Regorafenib","Afatinib","Dabrafenib and trametinib","Ribociclib","Lenvatinib","Pembrolizumab","Rucaparib","Axitinib","Palbociclib","Crizotinib","Sunitinib","Cabozantinib","Abemaciclib","Alectinib","Atezolizumab and Bevacizumab","Ipilimumab and nivolumab","Entrectinib","Talazoparib","Dacomitinib","Lorlatinib","Erdafitinib","Alpelisib","Niraparib","Pemigatinib","Selpercatinib","Tepotinib",{"trials":1000,"activeCount":98},[],{"trials":1002,"activeCount":98},[],{"trials":1004,"activeCount":98},[],{"intervention":83,"totalTrials":19,"cells":1006},{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1015,"PHASE3":1063,"PHASE4":1078,"NA":1080},{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[1011],{"nctId":803,"briefTitle":804,"status":131,"phases":1012,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":1013,"interventions":1014},[86],[811],[83,45],{"trials":1016,"activeCount":32,"soonestReadout":82},[1017,1021,1032,1036,1043,1047,1051,1055,1059],{"nctId":825,"briefTitle":826,"status":169,"phases":1018,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":1019,"interventions":1020},[87],[645],[83,45],{"nctId":1022,"briefTitle":1023,"status":110,"phases":1024,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1030},"NCT06342037","NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial",[87],"2026-04-01","2030-04-01","2024-06-12",60,[195],[1031,248,83],"Tiragolumab",{"nctId":839,"briefTitle":840,"status":131,"phases":1033,"primaryCompletion":842,"completion":843,"start":844,"enrollment":845,"conditions":1034,"interventions":1035},[86,87],[847,848],[45,83],{"nctId":80,"briefTitle":81,"status":217,"phases":1037,"primaryCompletion":82,"completion":1038,"start":1039,"enrollment":809,"conditions":1040,"interventions":1041},[87],"2026-06","2023-01-03",[26],[83,1042],"Cemiplimab",{"nctId":891,"briefTitle":892,"status":110,"phases":1044,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":1045,"interventions":1046},[87],[898],[45,83,900,901,902],{"nctId":904,"briefTitle":905,"status":131,"phases":1048,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":1049,"interventions":1050},[86,87],[645],[913,45,83],{"nctId":915,"briefTitle":916,"status":131,"phases":1052,"primaryCompletion":807,"completion":807,"start":918,"enrollment":919,"conditions":1053,"interventions":1054},[87],[861],[45,83],{"nctId":923,"briefTitle":924,"status":110,"phases":1056,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":1057,"interventions":1058},[86,87],[31],[83,45,45],{"nctId":933,"briefTitle":934,"status":110,"phases":1060,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":1061,"interventions":1062},[87],[15],[45,83,83],{"trials":1064,"activeCount":98},[1065],{"nctId":1066,"briefTitle":1067,"status":131,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1075},"NCT02278887","Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma",[88],"2022-09","2023-12-31","2014-09-23",168,[1074],"Metastatic Melanoma",[178,1076,1077,83],"Fludarabine","Interleukin-2",{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"intervention":978,"totalTrials":22,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":1158,"soonestReadout":1103},[1090,1099,1110,1118,1126,1140,1154],{"nctId":1091,"briefTitle":1092,"status":217,"phases":1093,"primaryCompletion":256,"completion":1094,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1098},"NCT05131919","Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers",[87],"2031-07","2022-12-22",25,[21],[978],{"nctId":1100,"briefTitle":1101,"status":217,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT04287829","Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients",[87],"2024-12-05","2026-03-05","2021-03-01",58,[1108],"Mesotheliomas Pleural",[978,977],{"nctId":1111,"briefTitle":1112,"status":169,"phases":1113,"primaryCompletion":1114,"completion":39,"start":1115,"enrollment":9,"conditions":1116,"interventions":1117},"NCT02625337","Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients",[87],"2018-06","2016-01",[1074],[978,966,968],{"nctId":1119,"briefTitle":1120,"status":131,"phases":1121,"primaryCompletion":1114,"completion":1114,"start":947,"enrollment":1122,"conditions":1123,"interventions":1124},"NCT02492568","Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC",[87],92,[186],[1125],"pembrolizumab",{"nctId":1127,"briefTitle":1128,"status":110,"phases":1129,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1138},"NCT06353906","Carboplatin\u002FPaclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer",[87],"2026-10-14","2028-01-14","2024-08-13",27,[877,878,885,1135,1136,1137],"Penile Cancer","Penile Squamous Cell Carcinoma","Locally Advanced Penile Carcinoma",[1139,978],"Carboplatin\u002FPaclitaxel",{"nctId":1141,"briefTitle":1142,"status":131,"phases":1143,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":845,"conditions":1147,"interventions":1151},"NCT03126812","Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer",[86,87],"2023-06-01","2024-03-05","2017-11-01",[1148,1149,1150],"Ovarian Cancer Stage IV","Peritoneal Cancer","Fallopian Tube Cancer",[1152,1153,978],"Carboplatin","Paclitaxel",{"nctId":952,"briefTitle":953,"status":110,"phases":1155,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1156,"interventions":1157},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],4,{"trials":1160,"activeCount":98},[],{"trials":1162,"activeCount":98},[],{"trials":1164,"activeCount":98},[],{"intervention":248,"totalTrials":32,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1182,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":94,"soonestReadout":1175},[1171],{"nctId":1172,"briefTitle":1173,"status":110,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1180},"NCT06012734","LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients",[86],"2026-07","2024-06-18",37,[1179],"Metastatic Microsatellite-stable Colorectal Cancer",[1181,248],"LB-100",{"trials":1183,"activeCount":230,"soonestReadout":242},[1184,1188,1198,1212],{"nctId":1022,"briefTitle":1023,"status":110,"phases":1185,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1028,"conditions":1186,"interventions":1187},[87],[195],[1031,248,83],{"nctId":1189,"briefTitle":1190,"status":153,"phases":1191,"primaryCompletion":1192,"completion":1193,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1197},"NCT03147040","AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer",[87],"2022-05-01","2022-07-01","2017-11-02",23,[15],[1152,248],{"nctId":1199,"briefTitle":1200,"status":217,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1208},"NCT03448835","Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)",[87],"2026-10-31","2018-03-07",20,[1206,1207],"Stomach Cancer","Gastro Esophageal Junction Cancer",[248,1209,1210,1211],"Capecitabine","Oxaliplatin","Docetaxel",{"nctId":239,"briefTitle":240,"status":217,"phases":1213,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":1214,"interventions":1215},[87],[246],[248,212],{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":98},[],{"intervention":60,"totalTrials":230,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1225,"activeCount":98},[],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":230,"soonestReadout":59},[1230,1238,1249],{"nctId":57,"briefTitle":58,"status":110,"phases":1231,"primaryCompletion":59,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1237},[87],"2029-01-01","2020-01-14",51,[1236],"Locally Advanced, Squamous Cell Carcinoma of the Vulva",[60],{"nctId":1239,"briefTitle":1240,"status":110,"phases":1241,"primaryCompletion":1242,"completion":1242,"start":59,"enrollment":1243,"conditions":1244,"interventions":1247},"NCT05905315","Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC",[87],"2029-09-01",98,[1245,1246],"Locally Advanced Vulvar Carcinoma","Squamous Cell Carcinoma of the Vulva",[60,1248],"Chemoradiation",{"nctId":62,"briefTitle":63,"status":110,"phases":1250,"primaryCompletion":59,"completion":1232,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1255},[87],"2020-01-16",12,[1254],"Metastatic Squamous Cell Carcinoma of the Vulva",[60],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[],{"intervention":1153,"totalTrials":27,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1311,"PHASE4":1317,"NA":1319},{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":279,"soonestReadout":72},[1270,1278,1288,1296,1300],{"nctId":70,"briefTitle":71,"status":217,"phases":1271,"primaryCompletion":72,"completion":366,"start":1272,"enrollment":1273,"conditions":1274,"interventions":1275},[87],"2013-07",304,[15],[73,1276,1153,1277],"Carbo\u002Fcyclo + atezolizumab","Paclitaxel + Atezolizumab",{"nctId":1279,"briefTitle":1280,"status":131,"phases":1281,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1287},"NCT03871036","Improve Checkpoint-blockade Response in Advanced Urothelial Cancer",[86,87],"2023-09-07","2025-01-15","2019-05-01",53,[811],[162,161,1153],{"nctId":1289,"briefTitle":1290,"status":153,"phases":1291,"primaryCompletion":221,"completion":221,"start":1292,"enrollment":94,"conditions":1293,"interventions":1295},"NCT03852979","Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility",[87],"2018-11-01",[1294],"Cervical Cancer",[1153,1152],{"nctId":1141,"briefTitle":1142,"status":131,"phases":1297,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":845,"conditions":1298,"interventions":1299},[86,87],[1148,1149,1150],[1152,1153,978],{"nctId":1301,"briefTitle":1302,"status":217,"phases":1303,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT02931890","Multicentric Randomised Trial for Resectable Gastric Cancer",[87],"2025-04","2029-03","2017-12-21",207,[1309],"Gastric Cancer",[1211,1210,1209,1153,1152],{"trials":1312,"activeCount":98},[1313],{"nctId":200,"briefTitle":201,"status":169,"phases":1314,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":1315,"interventions":1316},[88],[208],[210,211,212,163,213],{"trials":1318,"activeCount":98},[],{"trials":1320,"activeCount":98},[],{"intervention":1211,"totalTrials":32,"cells":1322},{"EARLY_PHASE1":1323,"PHASE1":1325,"PHASE2":1327,"PHASE3":1358,"PHASE4":1370,"NA":1372},{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":279,"soonestReadout":1304},[1329,1338,1342,1354],{"nctId":1330,"briefTitle":1331,"status":131,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":16,"conditions":1335,"interventions":1336},"NCT02039336","Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC",[86,87],"2018-08-07","2014-04-02",[21],[991,1337,1211],"PD-0325901",{"nctId":1199,"briefTitle":1200,"status":217,"phases":1339,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1340,"interventions":1341},[87],[1206,1207],[248,1209,1210,1211],{"nctId":1343,"briefTitle":1344,"status":169,"phases":1345,"primaryCompletion":143,"completion":1346,"start":1347,"enrollment":1348,"conditions":1349,"interventions":1352},"NCT02450656","Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",[86,87],"2019-12","2015-06",320,[768,1350,1351,26],"Gastrointestinal Neoplasms","Pancreatic Neoplasms",[974,1353,1211],"Selumetinib",{"nctId":1301,"briefTitle":1302,"status":217,"phases":1355,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1356,"interventions":1357},[87],[1309],[1211,1210,1209,1153,1152],{"trials":1359,"activeCount":98},[1360],{"nctId":1361,"briefTitle":1362,"status":153,"phases":1363,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1369},"NCT02775006","Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma",[88],"2019-04","2016-10-14",45,[1368],"Carcinoma, Non-small Cell Lung",[1211,969],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"intervention":1209,"totalTrials":230,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1390,"PHASE4":1404,"NA":1406},{"trials":1377,"activeCount":98},[],{"trials":1379,"activeCount":98},[],{"trials":1381,"activeCount":279,"soonestReadout":1304},[1382,1386],{"nctId":1199,"briefTitle":1200,"status":217,"phases":1383,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1384,"interventions":1385},[87],[1206,1207],[248,1209,1210,1211],{"nctId":1301,"briefTitle":1302,"status":217,"phases":1387,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1388,"interventions":1389},[87],[1309],[1211,1210,1209,1153,1152],{"trials":1391,"activeCount":98},[1392],{"nctId":1393,"briefTitle":1394,"status":153,"phases":1395,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":1399,"conditions":1400,"interventions":1401},"NCT00684216","Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer",[87,88],"2012-05","2013-05","2008-04",10,[15],[1402,1403],"capecitabine","hormonal treatment",{"trials":1405,"activeCount":98},[],{"trials":1407,"activeCount":98},[],{"intervention":149,"totalTrials":32,"cells":1409},{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1442,"PHASE3":1459,"PHASE4":1461,"NA":1463},{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[1414,1425,1429],{"nctId":1415,"briefTitle":1416,"status":169,"phases":1417,"primaryCompletion":1233,"completion":1418,"start":1419,"enrollment":1252,"conditions":1420,"interventions":1424},"NCT02229656","Olaparib and Radiotherapy in Head and Neck Cancer",[86],"2024-01","2014-09-24",[1421,1422,1423,848],"Laryngeal Cancer Stage II","Laryngeal Cancer Stage III","Carcinoma, Squamous Cell",[149],{"nctId":140,"briefTitle":141,"status":131,"phases":1426,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":1427,"interventions":1428},[86],[34],[149,121],{"nctId":1430,"briefTitle":1431,"status":131,"phases":1432,"primaryCompletion":1433,"completion":1434,"start":1435,"enrollment":22,"conditions":1436,"interventions":1440},"NCT02227082","Olaparib and Radiotherapy in Inoperable Breast Cancer",[86],"2019-09","2020-08","2013-10-21",[1437,1438,1439],"Locally Advanced Malignant Neoplasm","Inflammatory Breast Carcinoma","Triple-Negative Invasive Breast Carcinoma",[1441],"olaparib",{"trials":1443,"activeCount":279,"soonestReadout":1448},[1444,1455],{"nctId":1445,"briefTitle":1446,"status":110,"phases":1447,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":1451,"conditions":1452,"interventions":1454},"NCT07460180","The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer",[86,87],"2027-05-01","2032-05-01","2025-05-01",55,[29,1453,1150],"Epithelial Cancer",[149],{"nctId":952,"briefTitle":953,"status":110,"phases":1456,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1457,"interventions":1458},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1460,"activeCount":98},[],{"trials":1462,"activeCount":98},[],{"trials":1464,"activeCount":98},[],{"intervention":977,"totalTrials":279,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":279,"soonestReadout":1103},[1473,1477],{"nctId":1100,"briefTitle":1101,"status":217,"phases":1474,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1475,"interventions":1476},[87],[1108],[978,977],{"nctId":952,"briefTitle":953,"status":110,"phases":1478,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1479,"interventions":1480},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1482,"activeCount":98},[],{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":98},[],{"intervention":1210,"totalTrials":279,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1503,"PHASE4":1505,"NA":1507},{"trials":1490,"activeCount":98},[],{"trials":1492,"activeCount":98},[],{"trials":1494,"activeCount":279,"soonestReadout":1304},[1495,1499],{"nctId":1199,"briefTitle":1200,"status":217,"phases":1496,"primaryCompletion":1202,"completion":1202,"start":1203,"enrollment":1204,"conditions":1497,"interventions":1498},[87],[1206,1207],[248,1209,1210,1211],{"nctId":1301,"briefTitle":1302,"status":217,"phases":1500,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1501,"interventions":1502},[87],[1309],[1211,1210,1209,1153,1152],{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":98},[],{"trials":1508,"activeCount":98},[],{"intervention":1152,"totalTrials":32,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1533,"PHASE4":1539,"NA":1541},{"trials":1512,"activeCount":98},[],{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":94,"soonestReadout":1304},[1517,1521,1525,1529],{"nctId":1189,"briefTitle":1190,"status":153,"phases":1518,"primaryCompletion":1192,"completion":1193,"start":1194,"enrollment":1195,"conditions":1519,"interventions":1520},[87],[15],[1152,248],{"nctId":1289,"briefTitle":1290,"status":153,"phases":1522,"primaryCompletion":221,"completion":221,"start":1292,"enrollment":94,"conditions":1523,"interventions":1524},[87],[1294],[1153,1152],{"nctId":1141,"briefTitle":1142,"status":131,"phases":1526,"primaryCompletion":1144,"completion":1145,"start":1146,"enrollment":845,"conditions":1527,"interventions":1528},[86,87],[1148,1149,1150],[1152,1153,978],{"nctId":1301,"briefTitle":1302,"status":217,"phases":1530,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":1307,"conditions":1531,"interventions":1532},[87],[1309],[1211,1210,1209,1153,1152],{"trials":1534,"activeCount":98},[1535],{"nctId":200,"briefTitle":201,"status":169,"phases":1536,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":1537,"interventions":1538},[88],[208],[210,211,212,163,213],{"trials":1540,"activeCount":98},[],{"trials":1542,"activeCount":98},[],{"intervention":969,"totalTrials":279,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1555,"PHASE4":1561,"NA":1563},{"trials":1546,"activeCount":98},[],{"trials":1548,"activeCount":98},[],{"trials":1550,"activeCount":94,"soonestReadout":955},[1551],{"nctId":952,"briefTitle":953,"status":110,"phases":1552,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1553,"interventions":1554},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1556,"activeCount":98},[1557],{"nctId":1361,"briefTitle":1362,"status":153,"phases":1558,"primaryCompletion":1364,"completion":1364,"start":1365,"enrollment":1366,"conditions":1559,"interventions":1560},[88],[1368],[1211,969],{"trials":1562,"activeCount":98},[],{"trials":1564,"activeCount":98},[],{"intervention":980,"totalTrials":230,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1593,"PHASE4":1595,"NA":1597},{"trials":1568,"activeCount":98},[],{"trials":1570,"activeCount":98},[],{"trials":1572,"activeCount":94,"soonestReadout":955},[1573,1577,1589],{"nctId":288,"briefTitle":289,"status":131,"phases":1574,"primaryCompletion":291,"completion":292,"start":293,"enrollment":9,"conditions":1575,"interventions":1576},[86,87],[295],[297,278],{"nctId":1578,"briefTitle":1579,"status":169,"phases":1580,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":1585,"interventions":1587},"NCT03341845","Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC",[87],"2023-01-31","2025-01-31","2018-03-28",40,[1586],"Renal Cell Carcinoma",[980,1588],"Avelumab",{"nctId":952,"briefTitle":953,"status":110,"phases":1590,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1591,"interventions":1592},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1594,"activeCount":98},[],{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"intervention":974,"totalTrials":230,"cells":1600},{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1602,"activeCount":98},[],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":94,"soonestReadout":955},[1607,1616,1620],{"nctId":1608,"briefTitle":1609,"status":131,"phases":1610,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":1177,"conditions":1613,"interventions":1614},"NCT03727724","Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer",[87],"2022-09-06","2018-12-04",[26],[974,1615],"Cetuximab",{"nctId":1343,"briefTitle":1344,"status":169,"phases":1617,"primaryCompletion":143,"completion":1346,"start":1347,"enrollment":1348,"conditions":1618,"interventions":1619},[86,87],[768,1350,1351,26],[974,1353,1211],{"nctId":952,"briefTitle":953,"status":110,"phases":1621,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1622,"interventions":1623},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":98},[],{"trials":1629,"activeCount":98},[],{"intervention":161,"totalTrials":230,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1640,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[1636],{"nctId":151,"briefTitle":152,"status":153,"phases":1637,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":1638,"interventions":1639},[86],[159],[161,162,163,121],{"trials":1641,"activeCount":94,"soonestReadout":955},[1642,1646],{"nctId":1279,"briefTitle":1280,"status":131,"phases":1643,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1644,"interventions":1645},[86,87],[811],[162,161,1153],{"nctId":952,"briefTitle":953,"status":110,"phases":1647,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1648,"interventions":1649},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1651,"activeCount":98},[],{"trials":1653,"activeCount":98},[],{"trials":1655,"activeCount":98},[],{"intervention":968,"totalTrials":230,"cells":1657},{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[],{"trials":1663,"activeCount":94,"soonestReadout":955},[1664,1668,1679],{"nctId":1111,"briefTitle":1112,"status":169,"phases":1665,"primaryCompletion":1114,"completion":39,"start":1115,"enrollment":9,"conditions":1666,"interventions":1667},[87],[1074],[978,966,968],{"nctId":1669,"briefTitle":1670,"status":131,"phases":1671,"primaryCompletion":1672,"completion":1673,"start":1674,"enrollment":16,"conditions":1675,"interventions":1676},"NCT02230553","Lapatinib Plus Trametinib in KRAS Mutant NSCLC",[86,87],"2019-07-29","2019-08-06","2014-10-07",[21],[1677,1678],"Lapatinib","trametinib",{"nctId":952,"briefTitle":953,"status":110,"phases":1680,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1681,"interventions":1682},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[],{"trials":1688,"activeCount":98},[],{"intervention":177,"totalTrials":279,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":98},[],{"trials":1696,"activeCount":94,"soonestReadout":44},[1697,1701],{"nctId":167,"briefTitle":168,"status":169,"phases":1698,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":1699,"interventions":1700},[87],[15],[45,177,178,121],{"nctId":42,"briefTitle":43,"status":110,"phases":1702,"primaryCompletion":44,"completion":191,"start":192,"enrollment":193,"conditions":1703,"interventions":1704},[87],[195],[45,121,177],{"trials":1706,"activeCount":98},[],{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[],{"intervention":991,"totalTrials":279,"cells":1712},{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1714,"activeCount":98},[],{"trials":1716,"activeCount":98},[],{"trials":1718,"activeCount":94,"soonestReadout":955},[1719,1723],{"nctId":1330,"briefTitle":1331,"status":131,"phases":1720,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":16,"conditions":1721,"interventions":1722},[86,87],[21],[991,1337,1211],{"nctId":952,"briefTitle":953,"status":110,"phases":1724,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1725,"interventions":1726},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"intervention":983,"totalTrials":279,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1749,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[1739],{"nctId":1740,"briefTitle":1741,"status":131,"phases":1742,"primaryCompletion":1743,"completion":1743,"start":1744,"enrollment":1745,"conditions":1746,"interventions":1748},"NCT01286896","Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors",[86],"2011-12-27","2011-04-11",43,[1747],"Malignant Solid Tumour",[983],{"trials":1750,"activeCount":94,"soonestReadout":955},[1751],{"nctId":952,"briefTitle":953,"status":110,"phases":1752,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1753,"interventions":1754},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1756,"activeCount":98},[],{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[],{"intervention":966,"totalTrials":279,"cells":1762},{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":94,"soonestReadout":955},[1769,1773],{"nctId":1111,"briefTitle":1112,"status":169,"phases":1770,"primaryCompletion":1114,"completion":39,"start":1115,"enrollment":9,"conditions":1771,"interventions":1772},[87],[1074],[978,966,968],{"nctId":952,"briefTitle":953,"status":110,"phases":1774,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1775,"interventions":1776},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[],{"intervention":995,"totalTrials":279,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1786,"activeCount":98},[],{"trials":1788,"activeCount":98},[],{"trials":1790,"activeCount":94,"soonestReadout":955},[1791,1799],{"nctId":1792,"briefTitle":1793,"status":153,"phases":1794,"primaryCompletion":1193,"completion":1193,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1798},"NCT02826512","A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients",[87],"2018-05-15",9,[15],[995],{"nctId":952,"briefTitle":953,"status":110,"phases":1800,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":1801,"interventions":1802},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":1804,"activeCount":98},[],{"trials":1806,"activeCount":98},[],{"trials":1808,"activeCount":98},[],{"intervention":1031,"totalTrials":94,"cells":1810},{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":94,"soonestReadout":1025},[1817],{"nctId":1022,"briefTitle":1023,"status":110,"phases":1818,"primaryCompletion":1025,"completion":1026,"start":1027,"enrollment":1028,"conditions":1819,"interventions":1820},[87],[195],[1031,248,83],{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[],{"intervention":1828,"totalTrials":94,"cells":1829},"Ipilimumab + nivolumab",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1831,"activeCount":98},[],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":94,"soonestReadout":1840},[1836],{"nctId":1837,"briefTitle":1838,"status":217,"phases":1839,"primaryCompletion":1840,"completion":1841,"start":1842,"enrollment":919,"conditions":1843,"interventions":1845},"NCT05200988","Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC",[87],"2025-09-05","2027-09-05","2022-03-14",[811,1844],"Bladder Cancer",[1828],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"intervention":73,"totalTrials":94,"cells":1853},{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":94,"soonestReadout":72},[1860],{"nctId":70,"briefTitle":71,"status":217,"phases":1861,"primaryCompletion":72,"completion":366,"start":1272,"enrollment":1273,"conditions":1862,"interventions":1863},[87],[15],[73,1276,1153,1277],{"trials":1865,"activeCount":98},[],{"trials":1867,"activeCount":98},[],{"trials":1869,"activeCount":98},[],{"intervention":1276,"totalTrials":94,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1882,"PHASE4":1884,"NA":1886},{"trials":1873,"activeCount":98},[],{"trials":1875,"activeCount":98},[],{"trials":1877,"activeCount":94,"soonestReadout":72},[1878],{"nctId":70,"briefTitle":71,"status":217,"phases":1879,"primaryCompletion":72,"completion":366,"start":1272,"enrollment":1273,"conditions":1880,"interventions":1881},[87],[15],[73,1276,1153,1277],{"trials":1883,"activeCount":98},[],{"trials":1885,"activeCount":98},[],{"trials":1887,"activeCount":98},[],{"intervention":1277,"totalTrials":94,"cells":1889},{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1900,"PHASE4":1902,"NA":1904},{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[],{"trials":1895,"activeCount":94,"soonestReadout":72},[1896],{"nctId":70,"briefTitle":71,"status":217,"phases":1897,"primaryCompletion":72,"completion":366,"start":1272,"enrollment":1273,"conditions":1898,"interventions":1899},[87],[15],[73,1276,1153,1277],{"trials":1901,"activeCount":98},[],{"trials":1903,"activeCount":98},[],{"trials":1905,"activeCount":98},[],{"intervention":1042,"totalTrials":94,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1909,"activeCount":98},[],{"trials":1911,"activeCount":98},[],{"trials":1913,"activeCount":94,"soonestReadout":82},[1914],{"nctId":80,"briefTitle":81,"status":217,"phases":1915,"primaryCompletion":82,"completion":1038,"start":1039,"enrollment":809,"conditions":1916,"interventions":1917},[87],[26],[83,1042],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[],{"intervention":863,"totalTrials":94,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":94,"soonestReadout":854},[1932],{"nctId":851,"briefTitle":852,"status":110,"phases":1933,"primaryCompletion":854,"completion":854,"start":855,"enrollment":856,"conditions":1934,"interventions":1935},[87],[858,859,860,861],[45,863],{"trials":1937,"activeCount":98},[],{"trials":1939,"activeCount":98},[],{"trials":1941,"activeCount":98},[],{"intervention":1943,"totalTrials":94,"cells":1944},"Trastuzumab deruxtecan",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1946,"activeCount":98},[],{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":94,"soonestReadout":476},[1951],{"nctId":1952,"briefTitle":1953,"status":110,"phases":1954,"primaryCompletion":476,"completion":1955,"start":1956,"enrollment":1957,"conditions":1958,"interventions":1960},"NCT05982678","Basket Study for Oligo-metastatic Breast Cancer",[87],"2034-10-01","2024-05-02",72,[1959],"HER2-positive Breast Cancer",[1943],{"trials":1962,"activeCount":98},[],{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[],{"intervention":1968,"totalTrials":94,"cells":1969},"89Zr-Patritumab deruxtecan",{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1988,"PHASE4":1990,"NA":1992},{"trials":1971,"activeCount":98},[],{"trials":1973,"activeCount":98},[],{"trials":1975,"activeCount":94,"soonestReadout":1448},[1976],{"nctId":1977,"briefTitle":1978,"status":110,"phases":1979,"primaryCompletion":1448,"completion":1980,"start":1981,"enrollment":1982,"conditions":1983,"interventions":1987},"NCT06222489","Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET\u002FCT",[87],"2028-05-01","2025-03-03",16,[1984,1985,1986],"Non-Small Cell Lung Carcinoma","Advanced Non-Small Cell Squamous Lung Cancer","EGFR Gene Mutation",[1968],{"trials":1989,"activeCount":98},[],{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[],{"intervention":889,"totalTrials":94,"cells":1995},{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":1997,"activeCount":98},[],{"trials":1999,"activeCount":98},[],{"trials":2001,"activeCount":94,"soonestReadout":872},[2002],{"nctId":869,"briefTitle":870,"status":110,"phases":2003,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":2004,"interventions":2005},[87],[877,878,879,880,881,882,883,884,885,886,887],[45,889],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[],{"trials":2011,"activeCount":98},[],{"intervention":900,"totalTrials":94,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2015,"activeCount":98},[],{"trials":2017,"activeCount":98},[],{"trials":2019,"activeCount":94,"soonestReadout":894},[2020],{"nctId":891,"briefTitle":892,"status":110,"phases":2021,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":2022,"interventions":2023},[87],[898],[45,83,900,901,902],{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"trials":2029,"activeCount":98},[],{"intervention":901,"totalTrials":94,"cells":2031},{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2033,"activeCount":98},[],{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":94,"soonestReadout":894},[2038],{"nctId":891,"briefTitle":892,"status":110,"phases":2039,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":2040,"interventions":2041},[87],[898],[45,83,900,901,902],{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"trials":2047,"activeCount":98},[],{"intervention":902,"totalTrials":94,"cells":2049},{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2060,"PHASE4":2062,"NA":2064},{"trials":2051,"activeCount":98},[],{"trials":2053,"activeCount":98},[],{"trials":2055,"activeCount":94,"soonestReadout":894},[2056],{"nctId":891,"briefTitle":892,"status":110,"phases":2057,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":2058,"interventions":2059},[87],[898],[45,83,900,901,902],{"trials":2061,"activeCount":98},[],{"trials":2063,"activeCount":98},[],{"trials":2065,"activeCount":98},[],{"intervention":2067,"totalTrials":94,"cells":2068},"Galunisertib plus capecitabine",{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2073,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2070,"activeCount":98},[],{"trials":2072,"activeCount":98},[],{"trials":2074,"activeCount":94,"soonestReadout":1304},[2075],{"nctId":2076,"briefTitle":2077,"status":110,"phases":2078,"primaryCompletion":1304,"completion":1304,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2083},"NCT05700656","Galunisertib Combined With Capecitabine in Advanced CRC With PM",[86,87],"2023-07-28",31,[2082,481],"Colorectal Cancer Metastatic",[2067],{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":98},[],{"trials":2089,"activeCount":98},[],{"intervention":2091,"totalTrials":94,"cells":2092},"Cisplatin 100 mg\u002Fm2",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":98},[],{"trials":2098,"activeCount":94,"soonestReadout":2103},[2099],{"nctId":2100,"briefTitle":2101,"status":217,"phases":2102,"primaryCompletion":2103,"completion":956,"start":2104,"enrollment":1584,"conditions":2105,"interventions":2108},"NCT05406674","Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer",[87],"2026-12","2022-06-15",[2106,1149,2107],"FIGO Stage III Ovarian Cancer","Fallopian Tube Carcinoma",[2091,2109],"Cisplatin 40 mg\u002Fl",{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":98},[],{"intervention":2109,"totalTrials":94,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2122,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":94,"soonestReadout":2103},[2124],{"nctId":2100,"briefTitle":2101,"status":217,"phases":2125,"primaryCompletion":2103,"completion":956,"start":2104,"enrollment":1584,"conditions":2126,"interventions":2127},[87],[2106,1149,2107],[2091,2109],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[],{"intervention":1139,"totalTrials":94,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2146,"PHASE4":2148,"NA":2150},{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":98},[],{"trials":2141,"activeCount":94,"soonestReadout":1130},[2142],{"nctId":1127,"briefTitle":1128,"status":110,"phases":2143,"primaryCompletion":1130,"completion":1131,"start":1132,"enrollment":1133,"conditions":2144,"interventions":2145},[87],[877,878,885,1135,1136,1137],[1139,978],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[],{"intervention":1248,"totalTrials":94,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":98},[],{"trials":2159,"activeCount":94,"soonestReadout":1242},[2160],{"nctId":1239,"briefTitle":1240,"status":110,"phases":2161,"primaryCompletion":1242,"completion":1242,"start":59,"enrollment":1243,"conditions":2162,"interventions":2163},[87],[1245,1246],[60,1248],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"trials":2169,"activeCount":98},[],{"intervention":2171,"totalTrials":94,"cells":2172},"Neoadjuvant nivolumab",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[],{"trials":2178,"activeCount":94,"soonestReadout":2183},[2179],{"nctId":2180,"briefTitle":2181,"status":217,"phases":2182,"primaryCompletion":2183,"completion":2184,"start":2185,"enrollment":2186,"conditions":2187,"interventions":2188},"NCT05148546","Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer",[87],"2025-04-22","2029-04","2022-04-28",69,[1586],[2171,2189,2190],"Neoadjuvant ipilimumab","Neoadjuvant relatlimab",{"trials":2192,"activeCount":98},[],{"trials":2194,"activeCount":98},[],{"trials":2196,"activeCount":98},[],{"intervention":2189,"totalTrials":94,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2200,"activeCount":98},[],{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":94,"soonestReadout":2183},[2205],{"nctId":2180,"briefTitle":2181,"status":217,"phases":2206,"primaryCompletion":2183,"completion":2184,"start":2185,"enrollment":2186,"conditions":2207,"interventions":2208},[87],[1586],[2171,2189,2190],{"trials":2210,"activeCount":98},[],{"trials":2212,"activeCount":98},[],{"trials":2214,"activeCount":98},[],{"intervention":2190,"totalTrials":94,"cells":2216},{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":94,"soonestReadout":2183},[2223],{"nctId":2180,"briefTitle":2181,"status":217,"phases":2224,"primaryCompletion":2183,"completion":2184,"start":2185,"enrollment":2186,"conditions":2225,"interventions":2226},[87],[1586],[2171,2189,2190],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"intervention":965,"totalTrials":94,"cells":2234},{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2245,"PHASE4":2247,"NA":2249},{"trials":2236,"activeCount":98},[],{"trials":2238,"activeCount":98},[],{"trials":2240,"activeCount":94,"soonestReadout":955},[2241],{"nctId":952,"briefTitle":953,"status":110,"phases":2242,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2243,"interventions":2244},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"intervention":967,"totalTrials":94,"cells":2252},{"EARLY_PHASE1":2253,"PHASE1":2255,"PHASE2":2257,"PHASE3":2263,"PHASE4":2265,"NA":2267},{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":98},[],{"trials":2258,"activeCount":94,"soonestReadout":955},[2259],{"nctId":952,"briefTitle":953,"status":110,"phases":2260,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2261,"interventions":2262},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"intervention":970,"totalTrials":94,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2272,"activeCount":98},[],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":94,"soonestReadout":955},[2277],{"nctId":952,"briefTitle":953,"status":110,"phases":2278,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2279,"interventions":2280},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2282,"activeCount":98},[],{"trials":2284,"activeCount":98},[],{"trials":2286,"activeCount":98},[],{"intervention":971,"totalTrials":94,"cells":2288},{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2299,"PHASE4":2301,"NA":2303},{"trials":2290,"activeCount":98},[],{"trials":2292,"activeCount":98},[],{"trials":2294,"activeCount":94,"soonestReadout":955},[2295],{"nctId":952,"briefTitle":953,"status":110,"phases":2296,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2297,"interventions":2298},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2300,"activeCount":98},[],{"trials":2302,"activeCount":98},[],{"trials":2304,"activeCount":98},[],{"intervention":972,"totalTrials":94,"cells":2306},{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2317,"PHASE4":2319,"NA":2321},{"trials":2308,"activeCount":98},[],{"trials":2310,"activeCount":98},[],{"trials":2312,"activeCount":94,"soonestReadout":955},[2313],{"nctId":952,"briefTitle":953,"status":110,"phases":2314,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2315,"interventions":2316},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2318,"activeCount":98},[],{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[],{"intervention":973,"totalTrials":94,"cells":2324},{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2326,"activeCount":98},[],{"trials":2328,"activeCount":98},[],{"trials":2330,"activeCount":94,"soonestReadout":955},[2331],{"nctId":952,"briefTitle":953,"status":110,"phases":2332,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2333,"interventions":2334},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"intervention":975,"totalTrials":94,"cells":2342},{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":94,"soonestReadout":955},[2349],{"nctId":952,"briefTitle":953,"status":110,"phases":2350,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2351,"interventions":2352},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[],{"intervention":976,"totalTrials":94,"cells":2360},{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2371,"PHASE4":2373,"NA":2375},{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":94,"soonestReadout":955},[2367],{"nctId":952,"briefTitle":953,"status":110,"phases":2368,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2369,"interventions":2370},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":98},[],{"trials":2376,"activeCount":98},[],{"intervention":979,"totalTrials":94,"cells":2378},{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2380,"activeCount":98},[],{"trials":2382,"activeCount":98},[],{"trials":2384,"activeCount":94,"soonestReadout":955},[2385],{"nctId":952,"briefTitle":953,"status":110,"phases":2386,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2387,"interventions":2388},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2390,"activeCount":98},[],{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[],{"intervention":981,"totalTrials":94,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2401,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2398,"activeCount":98},[],{"trials":2400,"activeCount":98},[],{"trials":2402,"activeCount":94,"soonestReadout":955},[2403],{"nctId":952,"briefTitle":953,"status":110,"phases":2404,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2405,"interventions":2406},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2408,"activeCount":98},[],{"trials":2410,"activeCount":98},[],{"trials":2412,"activeCount":98},[],{"intervention":982,"totalTrials":94,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2416,"activeCount":98},[],{"trials":2418,"activeCount":98},[],{"trials":2420,"activeCount":94,"soonestReadout":955},[2421],{"nctId":952,"briefTitle":953,"status":110,"phases":2422,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2423,"interventions":2424},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2426,"activeCount":98},[],{"trials":2428,"activeCount":98},[],{"trials":2430,"activeCount":98},[],{"intervention":984,"totalTrials":94,"cells":2432},{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2434,"activeCount":98},[],{"trials":2436,"activeCount":98},[],{"trials":2438,"activeCount":94,"soonestReadout":955},[2439],{"nctId":952,"briefTitle":953,"status":110,"phases":2440,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2441,"interventions":2442},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2444,"activeCount":98},[],{"trials":2446,"activeCount":98},[],{"trials":2448,"activeCount":98},[],{"intervention":985,"totalTrials":94,"cells":2450},{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2452,"activeCount":98},[],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":94,"soonestReadout":955},[2457],{"nctId":952,"briefTitle":953,"status":110,"phases":2458,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2459,"interventions":2460},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2462,"activeCount":98},[],{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[],{"intervention":986,"totalTrials":94,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2473,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2470,"activeCount":98},[],{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":94,"soonestReadout":955},[2475],{"nctId":952,"briefTitle":953,"status":110,"phases":2476,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2477,"interventions":2478},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2480,"activeCount":98},[],{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[],{"intervention":987,"totalTrials":94,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2488,"activeCount":98},[],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":94,"soonestReadout":955},[2493],{"nctId":952,"briefTitle":953,"status":110,"phases":2494,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2495,"interventions":2496},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2498,"activeCount":98},[],{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":98},[],{"intervention":988,"totalTrials":94,"cells":2504},{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2509,"PHASE3":2515,"PHASE4":2517,"NA":2519},{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[],{"trials":2510,"activeCount":94,"soonestReadout":955},[2511],{"nctId":952,"briefTitle":953,"status":110,"phases":2512,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2513,"interventions":2514},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2516,"activeCount":98},[],{"trials":2518,"activeCount":98},[],{"trials":2520,"activeCount":98},[],{"intervention":989,"totalTrials":94,"cells":2522},{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2527,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":94,"soonestReadout":955},[2529],{"nctId":952,"briefTitle":953,"status":110,"phases":2530,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2531,"interventions":2532},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[],{"trials":2538,"activeCount":98},[],{"intervention":990,"totalTrials":94,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2551,"PHASE4":2553,"NA":2555},{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":94,"soonestReadout":955},[2547],{"nctId":952,"briefTitle":953,"status":110,"phases":2548,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2549,"interventions":2550},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2552,"activeCount":98},[],{"trials":2554,"activeCount":98},[],{"trials":2556,"activeCount":98},[],{"intervention":992,"totalTrials":94,"cells":2558},{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2569,"PHASE4":2571,"NA":2573},{"trials":2560,"activeCount":98},[],{"trials":2562,"activeCount":98},[],{"trials":2564,"activeCount":94,"soonestReadout":955},[2565],{"nctId":952,"briefTitle":953,"status":110,"phases":2566,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2567,"interventions":2568},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"trials":2574,"activeCount":98},[],{"intervention":993,"totalTrials":94,"cells":2576},{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2587,"PHASE4":2589,"NA":2591},{"trials":2578,"activeCount":98},[],{"trials":2580,"activeCount":98},[],{"trials":2582,"activeCount":94,"soonestReadout":955},[2583],{"nctId":952,"briefTitle":953,"status":110,"phases":2584,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2585,"interventions":2586},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2588,"activeCount":98},[],{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"intervention":994,"totalTrials":94,"cells":2594},{"EARLY_PHASE1":2595,"PHASE1":2597,"PHASE2":2599,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2596,"activeCount":98},[],{"trials":2598,"activeCount":98},[],{"trials":2600,"activeCount":94,"soonestReadout":955},[2601],{"nctId":952,"briefTitle":953,"status":110,"phases":2602,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2603,"interventions":2604},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2606,"activeCount":98},[],{"trials":2608,"activeCount":98},[],{"trials":2610,"activeCount":98},[],{"intervention":996,"totalTrials":94,"cells":2612},{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2623,"PHASE4":2625,"NA":2627},{"trials":2614,"activeCount":98},[],{"trials":2616,"activeCount":98},[],{"trials":2618,"activeCount":94,"soonestReadout":955},[2619],{"nctId":952,"briefTitle":953,"status":110,"phases":2620,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2621,"interventions":2622},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2624,"activeCount":98},[],{"trials":2626,"activeCount":98},[],{"trials":2628,"activeCount":98},[],{"intervention":997,"totalTrials":94,"cells":2630},{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2635,"PHASE3":2641,"PHASE4":2643,"NA":2645},{"trials":2632,"activeCount":98},[],{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":94,"soonestReadout":955},[2637],{"nctId":952,"briefTitle":953,"status":110,"phases":2638,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2639,"interventions":2640},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2642,"activeCount":98},[],{"trials":2644,"activeCount":98},[],{"trials":2646,"activeCount":98},[],{"intervention":998,"totalTrials":94,"cells":2648},{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2659,"PHASE4":2661,"NA":2663},{"trials":2650,"activeCount":98},[],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":94,"soonestReadout":955},[2655],{"nctId":952,"briefTitle":953,"status":110,"phases":2656,"primaryCompletion":955,"completion":956,"start":957,"enrollment":958,"conditions":2657,"interventions":2658},[87],[960,961,962,963],[965,149,966,967,968,969,970,971,972,973,45,974,975,976,977,978,161,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998],{"trials":2660,"activeCount":98},[],{"trials":2662,"activeCount":98},[],{"trials":2664,"activeCount":98},[],{"intervention":2666,"totalTrials":279,"cells":2667},"Trastuzumab",{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2684,"PHASE3":2696,"PHASE4":2698,"NA":2700},{"trials":2669,"activeCount":98},[],{"trials":2671,"activeCount":94,"soonestReadout":2676},[2672],{"nctId":2673,"briefTitle":2674,"status":110,"phases":2675,"primaryCompletion":2676,"completion":2677,"start":2678,"enrollment":2679,"conditions":2680,"interventions":2681},"NCT06162559","Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study",[86],"2026-08","2036-05","2023-12-18",30,[15],[2682,2666,2683],"Tucatinib","Pertuzumab",{"trials":2685,"activeCount":98},[2686],{"nctId":2687,"briefTitle":2688,"status":131,"phases":2689,"primaryCompletion":2690,"completion":2691,"start":2692,"enrollment":1252,"conditions":2693,"interventions":2694},"NCT04307329","Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial",[87],"2023-01-19","2024-03-23","2021-03-23",[15],[2695,2666],"Monalizumab",{"trials":2697,"activeCount":98},[],{"trials":2699,"activeCount":98},[],{"trials":2701,"activeCount":98},[],{"intervention":2682,"totalTrials":94,"cells":2703},{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2712,"PHASE3":2714,"PHASE4":2716,"NA":2718},{"trials":2705,"activeCount":98},[],{"trials":2707,"activeCount":94,"soonestReadout":2676},[2708],{"nctId":2673,"briefTitle":2674,"status":110,"phases":2709,"primaryCompletion":2676,"completion":2677,"start":2678,"enrollment":2679,"conditions":2710,"interventions":2711},[86],[15],[2682,2666,2683],{"trials":2713,"activeCount":98},[],{"trials":2715,"activeCount":98},[],{"trials":2717,"activeCount":98},[],{"trials":2719,"activeCount":98},[],{"intervention":2683,"totalTrials":94,"cells":2721},{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2730,"PHASE3":2732,"PHASE4":2734,"NA":2736},{"trials":2723,"activeCount":98},[],{"trials":2725,"activeCount":94,"soonestReadout":2676},[2726],{"nctId":2673,"briefTitle":2674,"status":110,"phases":2727,"primaryCompletion":2676,"completion":2677,"start":2678,"enrollment":2679,"conditions":2728,"interventions":2729},[86],[15],[2682,2666,2683],{"trials":2731,"activeCount":98},[],{"trials":2733,"activeCount":98},[],{"trials":2735,"activeCount":98},[],{"trials":2737,"activeCount":98},[],{"intervention":1181,"totalTrials":94,"cells":2739},{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2748,"PHASE3":2750,"PHASE4":2752,"NA":2754},{"trials":2741,"activeCount":98},[],{"trials":2743,"activeCount":94,"soonestReadout":1175},[2744],{"nctId":1172,"briefTitle":1173,"status":110,"phases":2745,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":2746,"interventions":2747},[86],[1179],[1181,248],{"trials":2749,"activeCount":98},[],{"trials":2751,"activeCount":98},[],{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[],{"intervention":2757,"totalTrials":94,"cells":2758},"Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan",{"EARLY_PHASE1":2759,"PHASE1":2761,"PHASE2":2763,"PHASE3":2765,"PHASE4":2767,"NA":2769},{"trials":2760,"activeCount":98},[],{"trials":2762,"activeCount":98},[],{"trials":2764,"activeCount":98},[],{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":98},[],{"trials":2770,"activeCount":94,"soonestReadout":172},[2771],{"nctId":2772,"briefTitle":2773,"status":110,"phases":2774,"primaryCompletion":172,"completion":172,"start":2775,"enrollment":2776,"conditions":2777,"interventions":2779},"NCT06666634","Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy",[90],"2023-04-01",29,[1135,31,2778],"Oral Cancer",[2757],{"intervention":2781,"totalTrials":94,"cells":2782},"Adjuvant chemotherapy",{"EARLY_PHASE1":2783,"PHASE1":2785,"PHASE2":2787,"PHASE3":2789,"PHASE4":2791,"NA":2793},{"trials":2784,"activeCount":98},[],{"trials":2786,"activeCount":98},[],{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":94,"soonestReadout":2799},[2795],{"nctId":2796,"briefTitle":2797,"status":110,"phases":2798,"primaryCompletion":2799,"completion":2800,"start":2801,"enrollment":2802,"conditions":2803,"interventions":2806},"NCT06476119","OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes",[],"2032-09-15","2034-09-15","2025-04-15",490,[2804,2805],"Breast Cancer Stage I","Triple Negative Breast Cancer (TNBC)",[2781],{"intervention":2808,"totalTrials":94,"cells":2809},"Piracetam",{"EARLY_PHASE1":2810,"PHASE1":2812,"PHASE2":2814,"PHASE3":2816,"PHASE4":2818,"NA":2829},{"trials":2811,"activeCount":98},[],{"trials":2813,"activeCount":98},[],{"trials":2815,"activeCount":98},[],{"trials":2817,"activeCount":98},[],{"trials":2819,"activeCount":98},[2820],{"nctId":2821,"briefTitle":2822,"status":169,"phases":2823,"primaryCompletion":2824,"completion":2824,"start":2825,"enrollment":1399,"conditions":2826,"interventions":2828},"NCT05918341","Subtherapeutic Dose of Piracetam as a Therapy Adherence Marker",[89],"2023-09-30","2023-07-03",[2827],"Drug Adherence Marker",[2808],{"trials":2830,"activeCount":98},[],{"intervention":163,"totalTrials":230,"cells":2832},{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2841,"PHASE3":2847,"PHASE4":2853,"NA":2855},{"trials":2834,"activeCount":98},[],{"trials":2836,"activeCount":98},[2837],{"nctId":151,"briefTitle":152,"status":153,"phases":2838,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":2839,"interventions":2840},[86],[159],[161,162,163,121],{"trials":2842,"activeCount":98},[2843],{"nctId":180,"briefTitle":181,"status":182,"phases":2844,"primaryCompletion":184,"completion":184,"start":184,"enrollment":98,"conditions":2845,"interventions":2846},[87],[186],[121,163,188],{"trials":2848,"activeCount":98},[2849],{"nctId":200,"briefTitle":201,"status":169,"phases":2850,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":2851,"interventions":2852},[88],[208],[210,211,212,163,213],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"intervention":178,"totalTrials":279,"cells":2858},{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2863,"PHASE3":2869,"PHASE4":2875,"NA":2877},{"trials":2860,"activeCount":98},[],{"trials":2862,"activeCount":98},[],{"trials":2864,"activeCount":98},[2865],{"nctId":167,"briefTitle":168,"status":169,"phases":2866,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":2867,"interventions":2868},[87],[15],[45,177,178,121],{"trials":2870,"activeCount":98},[2871],{"nctId":1066,"briefTitle":1067,"status":131,"phases":2872,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":2873,"interventions":2874},[88],[1074],[178,1076,1077,83],{"trials":2876,"activeCount":98},[],{"trials":2878,"activeCount":98},[],{"intervention":2880,"totalTrials":279,"cells":2881},"Enzalutamide",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2898,"PHASE4":2913,"NA":2915},{"trials":2883,"activeCount":98},[],{"trials":2885,"activeCount":98},[],{"trials":2887,"activeCount":98},[2888],{"nctId":2889,"briefTitle":2890,"status":131,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":919,"conditions":2894,"interventions":2897},"NCT03297385","Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation",[87],"2017-04-01","2014-08-28",[18,2895,2896],"DNA","Androgen Receptor Abnormal",[2880],{"trials":2899,"activeCount":98},[2900],{"nctId":2901,"briefTitle":2902,"status":131,"phases":2903,"primaryCompletion":2904,"completion":2905,"start":2906,"enrollment":328,"conditions":2907,"interventions":2910},"NCT03295565","Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel",[87,88],"2020-12-16","2022-03-02","2017-05-07",[2908,2909],"Prostate Cancer Metastatic","Metastasis",[2911,2912,2880],"Cabazitaxel","Abiraterone",{"trials":2914,"activeCount":98},[],{"trials":2916,"activeCount":98},[],{"intervention":2918,"totalTrials":94,"cells":2919},"cisplatinum",{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2938,"NA":2940},{"trials":2921,"activeCount":98},[],{"trials":2923,"activeCount":98},[],{"trials":2925,"activeCount":98},[],{"trials":2927,"activeCount":98},[2928],{"nctId":2929,"briefTitle":2930,"status":131,"phases":2931,"primaryCompletion":2932,"completion":2933,"start":2934,"enrollment":2935,"conditions":2936,"interventions":2937},"NCT01504815","Adaptive Radiation Treatment for Head and Neck Cancer",[88],"2021-12-01","2024-12-24","2012-09-07",268,[24],[2918],{"trials":2939,"activeCount":98},[],{"trials":2941,"activeCount":98},[],{"intervention":769,"totalTrials":94,"cells":2943},{"EARLY_PHASE1":2944,"PHASE1":2946,"PHASE2":2948,"PHASE3":2950,"PHASE4":2961,"NA":2963},{"trials":2945,"activeCount":98},[],{"trials":2947,"activeCount":98},[],{"trials":2949,"activeCount":98},[],{"trials":2951,"activeCount":98},[2952],{"nctId":2953,"briefTitle":2954,"status":169,"phases":2955,"primaryCompletion":2956,"completion":2957,"start":2958,"enrollment":2080,"conditions":2959,"interventions":2960},"NCT04552093","Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)",[87,88],"2022-06-30","2022-12-31","2020-09-09",[768],[769],{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"intervention":1403,"totalTrials":94,"cells":2966},{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2973,"PHASE4":2979,"NA":2981},{"trials":2968,"activeCount":98},[],{"trials":2970,"activeCount":98},[],{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":98},[2975],{"nctId":1393,"briefTitle":1394,"status":153,"phases":2976,"primaryCompletion":1396,"completion":1397,"start":1398,"enrollment":1399,"conditions":2977,"interventions":2978},[87,88],[15],[1402,1403],{"trials":2980,"activeCount":98},[],{"trials":2982,"activeCount":98},[],{"intervention":2984,"totalTrials":94,"cells":2985},"Intensified Cyclophophamide, Carboplatin and Thiotepa",{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":2992,"PHASE4":3004,"NA":3006},{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[],{"trials":2991,"activeCount":98},[],{"trials":2993,"activeCount":98},[2994],{"nctId":2995,"briefTitle":2996,"status":153,"phases":2997,"primaryCompletion":2998,"completion":2999,"start":3000,"enrollment":1252,"conditions":3001,"interventions":3002},"NCT00448266","Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD",[87,88],"2010-02","2011-02","2007-05",[15],[2984,3003],"dose dense adriamycine and cyclophosphamide",{"trials":3005,"activeCount":98},[],{"trials":3007,"activeCount":98},[],{"intervention":3003,"totalTrials":94,"cells":3009},{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3014,"PHASE3":3016,"PHASE4":3022,"NA":3024},{"trials":3011,"activeCount":98},[],{"trials":3013,"activeCount":98},[],{"trials":3015,"activeCount":98},[],{"trials":3017,"activeCount":98},[3018],{"nctId":2995,"briefTitle":2996,"status":153,"phases":3019,"primaryCompletion":2998,"completion":2999,"start":3000,"enrollment":1252,"conditions":3020,"interventions":3021},[87,88],[15],[2984,3003],{"trials":3023,"activeCount":98},[],{"trials":3025,"activeCount":98},[],{"intervention":3027,"totalTrials":94,"cells":3028},"AT1 blocker candesartan",{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3033,"PHASE3":3035,"PHASE4":3046,"NA":3048},{"trials":3030,"activeCount":98},[],{"trials":3032,"activeCount":98},[],{"trials":3034,"activeCount":98},[],{"trials":3036,"activeCount":98},[3037],{"nctId":3038,"briefTitle":3039,"status":131,"phases":3040,"primaryCompletion":367,"completion":3041,"start":3042,"enrollment":3043,"conditions":3044,"interventions":3045},"NCT00459771","Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity",[88],"2014-12","2007-06",210,[15],[3027],{"trials":3047,"activeCount":98},[],{"trials":3049,"activeCount":98},[],{"intervention":1076,"totalTrials":94,"cells":3051},{"EARLY_PHASE1":3052,"PHASE1":3054,"PHASE2":3056,"PHASE3":3058,"PHASE4":3064,"NA":3066},{"trials":3053,"activeCount":98},[],{"trials":3055,"activeCount":98},[],{"trials":3057,"activeCount":98},[],{"trials":3059,"activeCount":98},[3060],{"nctId":1066,"briefTitle":1067,"status":131,"phases":3061,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":3062,"interventions":3063},[88],[1074],[178,1076,1077,83],{"trials":3065,"activeCount":98},[],{"trials":3067,"activeCount":98},[],{"intervention":1077,"totalTrials":94,"cells":3069},{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3076,"PHASE4":3082,"NA":3084},{"trials":3071,"activeCount":98},[],{"trials":3073,"activeCount":98},[],{"trials":3075,"activeCount":98},[],{"trials":3077,"activeCount":98},[3078],{"nctId":1066,"briefTitle":1067,"status":131,"phases":3079,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":3080,"interventions":3081},[88],[1074],[178,1076,1077,83],{"trials":3083,"activeCount":98},[],{"trials":3085,"activeCount":98},[],{"intervention":2911,"totalTrials":94,"cells":3087},{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3094,"PHASE4":3100,"NA":3102},{"trials":3089,"activeCount":98},[],{"trials":3091,"activeCount":98},[],{"trials":3093,"activeCount":98},[],{"trials":3095,"activeCount":98},[3096],{"nctId":2901,"briefTitle":2902,"status":131,"phases":3097,"primaryCompletion":2904,"completion":2905,"start":2906,"enrollment":328,"conditions":3098,"interventions":3099},[87,88],[2908,2909],[2911,2912,2880],{"trials":3101,"activeCount":98},[],{"trials":3103,"activeCount":98},[],{"intervention":2912,"totalTrials":94,"cells":3105},{"EARLY_PHASE1":3106,"PHASE1":3108,"PHASE2":3110,"PHASE3":3112,"PHASE4":3118,"NA":3120},{"trials":3107,"activeCount":98},[],{"trials":3109,"activeCount":98},[],{"trials":3111,"activeCount":98},[],{"trials":3113,"activeCount":98},[3114],{"nctId":2901,"briefTitle":2902,"status":131,"phases":3115,"primaryCompletion":2904,"completion":2905,"start":2906,"enrollment":328,"conditions":3116,"interventions":3117},[87,88],[2908,2909],[2911,2912,2880],{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[],{"intervention":1615,"totalTrials":230,"cells":3123},{"EARLY_PHASE1":3124,"PHASE1":3126,"PHASE2":3140,"PHASE3":3157,"PHASE4":3159,"NA":3161},{"trials":3125,"activeCount":98},[],{"trials":3127,"activeCount":98},[3128],{"nctId":3129,"briefTitle":3130,"status":131,"phases":3131,"primaryCompletion":3132,"completion":3133,"start":3134,"enrollment":1399,"conditions":3135,"interventions":3137},"NCT02938273","Bioimmunoradiotherapy (Cetuximab\u002FRT\u002FAvelumab)",[86],"2019-06-26","2019-09-30","2017-02-01",[3136],"Carcinoma, Squamous Cell of Head and Neck",[3138,3139],"avelumab","cetuximab",{"trials":3141,"activeCount":98},[3142,3146],{"nctId":1608,"briefTitle":1609,"status":131,"phases":3143,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":1177,"conditions":3144,"interventions":3145},[87],[26],[974,1615],{"nctId":3147,"briefTitle":3148,"status":182,"phases":3149,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":98,"conditions":3152,"interventions":3156},"NCT04648189","Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC",[87],"2022-09-19","2022-01-01",[3153,3154,3155],"Lung Cancer","Surgery","Circulating Tumor Cell",[1615],{"trials":3158,"activeCount":98},[],{"trials":3160,"activeCount":98},[],{"trials":3162,"activeCount":98},[],{"intervention":3164,"totalTrials":279,"cells":3165},"Tamoxifen",{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3194,"PHASE4":3196,"NA":3198},{"trials":3167,"activeCount":98},[],{"trials":3169,"activeCount":98},[],{"trials":3171,"activeCount":98},[3172,3181],{"nctId":3173,"briefTitle":3174,"status":131,"phases":3175,"primaryCompletion":1192,"completion":1192,"start":3176,"enrollment":3177,"conditions":3178,"interventions":3179},"NCT02285179","Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen",[86,87],"2014-11",189,[15],[3180,3164],"GDC-0032",{"nctId":3182,"briefTitle":3183,"status":3184,"phases":3185,"primaryCompletion":3186,"completion":3187,"start":3188,"enrollment":3189,"conditions":3190,"interventions":3191},"NCT00738777","Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer","SUSPENDED",[87],"2022-06","2024-06","2008-07",250,[15],[3192,3193,3164,3164],"Anastrozole","Anastrozole+Fulvestrant",{"trials":3195,"activeCount":98},[],{"trials":3197,"activeCount":98},[],{"trials":3199,"activeCount":98},[],{"intervention":1588,"totalTrials":279,"cells":3201},{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3210,"PHASE3":3216,"PHASE4":3218,"NA":3220},{"trials":3203,"activeCount":98},[],{"trials":3205,"activeCount":98},[3206],{"nctId":3129,"briefTitle":3130,"status":131,"phases":3207,"primaryCompletion":3132,"completion":3133,"start":3134,"enrollment":1399,"conditions":3208,"interventions":3209},[86],[3136],[3138,3139],{"trials":3211,"activeCount":98},[3212],{"nctId":1578,"briefTitle":1579,"status":169,"phases":3213,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":3214,"interventions":3215},[87],[1586],[980,1588],{"trials":3217,"activeCount":98},[],{"trials":3219,"activeCount":98},[],{"trials":3221,"activeCount":98},[],{"intervention":3223,"totalTrials":279,"cells":3224},"pazopanib",{"EARLY_PHASE1":3225,"PHASE1":3227,"PHASE2":3238,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3226,"activeCount":98},[],{"trials":3228,"activeCount":98},[3229],{"nctId":3230,"briefTitle":3231,"status":131,"phases":3232,"primaryCompletion":3233,"completion":3176,"start":3234,"enrollment":1252,"conditions":3235,"interventions":3237},"NCT01985295","Combined Modality Treatment of Sarcomas of the Extremities",[86],"2014-08","2010-06",[3236],"Sarcoma,Soft Tissue",[3223],{"trials":3239,"activeCount":98},[3240],{"nctId":3241,"briefTitle":3242,"status":153,"phases":3243,"primaryCompletion":3244,"completion":3244,"start":3245,"enrollment":1096,"conditions":3246,"interventions":3249},"NCT02575066","Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients",[87],"2019-03-20","2016-03-17",[3247,3248],"Sarcoma","Soft Tissue Sarcomas",[3223],{"trials":3251,"activeCount":98},[],{"trials":3253,"activeCount":98},[],{"trials":3255,"activeCount":98},[],{"intervention":162,"totalTrials":279,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3266,"PHASE3":3272,"PHASE4":3274,"NA":3276},{"trials":3259,"activeCount":98},[],{"trials":3261,"activeCount":98},[3262],{"nctId":151,"briefTitle":152,"status":153,"phases":3263,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":3264,"interventions":3265},[86],[159],[161,162,163,121],{"trials":3267,"activeCount":98},[3268],{"nctId":1279,"briefTitle":1280,"status":131,"phases":3269,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":3270,"interventions":3271},[86,87],[811],[162,161,1153],{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[],{"trials":3277,"activeCount":98},[],{"intervention":3180,"totalTrials":94,"cells":3279},{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3284,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3281,"activeCount":98},[],{"trials":3283,"activeCount":98},[],{"trials":3285,"activeCount":98},[3286],{"nctId":3173,"briefTitle":3174,"status":131,"phases":3287,"primaryCompletion":1192,"completion":1192,"start":3176,"enrollment":3177,"conditions":3288,"interventions":3289},[86,87],[15],[3180,3164],{"trials":3291,"activeCount":98},[],{"trials":3293,"activeCount":98},[],{"trials":3295,"activeCount":98},[],{"intervention":3297,"totalTrials":94,"cells":3298},"ADT",{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3314,"PHASE4":3316,"NA":3318},{"trials":3300,"activeCount":98},[],{"trials":3302,"activeCount":98},[],{"trials":3304,"activeCount":98},[3305],{"nctId":3306,"briefTitle":3307,"status":169,"phases":3308,"primaryCompletion":3309,"completion":3310,"start":3311,"enrollment":1028,"conditions":3312,"interventions":3313},"NCT05555017","Tracer-Guided Surgery for Recurrent Prostate Cancer",[87],"2024-11","2025-11","2023-02-15",[18],[3297],{"trials":3315,"activeCount":98},[],{"trials":3317,"activeCount":98},[],{"trials":3319,"activeCount":98},[],{"intervention":3321,"totalTrials":94,"cells":3322},"2B3-101",{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3324,"activeCount":98},[],{"trials":3326,"activeCount":98},[],{"trials":3328,"activeCount":98},[3329],{"nctId":3330,"briefTitle":3331,"status":169,"phases":3332,"primaryCompletion":3333,"completion":3333,"start":3334,"enrollment":27,"conditions":3335,"interventions":3337},"NCT01818713","Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases",[87],"2014-10","2013-10",[3336],"Meningeal Carcinomatosis",[3321],{"trials":3339,"activeCount":98},[],{"trials":3341,"activeCount":98},[],{"trials":3343,"activeCount":98},[],{"intervention":3345,"totalTrials":94,"cells":3346},"Trastuzumab emtansine",{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":98},[],{"trials":3352,"activeCount":98},[3353],{"nctId":3354,"briefTitle":3355,"status":153,"phases":3356,"primaryCompletion":3357,"completion":3357,"start":3358,"enrollment":146,"conditions":3359,"interventions":3360},"NCT03784599","T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC",[87],"2021-05-17","2018-12-18",[26],[3345,3361],"Osimertinib",{"trials":3363,"activeCount":98},[],{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"intervention":3361,"totalTrials":94,"cells":3369},{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3374,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3371,"activeCount":98},[],{"trials":3373,"activeCount":98},[],{"trials":3375,"activeCount":98},[3376],{"nctId":3354,"briefTitle":3355,"status":153,"phases":3377,"primaryCompletion":3357,"completion":3357,"start":3358,"enrollment":146,"conditions":3378,"interventions":3379},[87],[26],[3345,3361],{"trials":3381,"activeCount":98},[],{"trials":3383,"activeCount":98},[],{"trials":3385,"activeCount":98},[],{"intervention":2695,"totalTrials":94,"cells":3387},{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3398,"PHASE4":3400,"NA":3402},{"trials":3389,"activeCount":98},[],{"trials":3391,"activeCount":98},[],{"trials":3393,"activeCount":98},[3394],{"nctId":2687,"briefTitle":2688,"status":131,"phases":3395,"primaryCompletion":2690,"completion":2691,"start":2692,"enrollment":1252,"conditions":3396,"interventions":3397},[87],[15],[2695,2666],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":98},[],{"trials":3403,"activeCount":98},[],{"intervention":3405,"totalTrials":94,"cells":3406},"cisplatinum and everolimus",{"EARLY_PHASE1":3407,"PHASE1":3409,"PHASE2":3411,"PHASE3":3423,"PHASE4":3425,"NA":3427},{"trials":3408,"activeCount":98},[],{"trials":3410,"activeCount":98},[],{"trials":3412,"activeCount":98},[3413],{"nctId":3414,"briefTitle":3415,"status":169,"phases":3416,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":737,"conditions":3420,"interventions":3422},"NCT02695459","Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin",[87],"2021-04","2021-08","2016-03-30",[3421],"Neuroendocrine Carcinomas",[3405],{"trials":3424,"activeCount":98},[],{"trials":3426,"activeCount":98},[],{"trials":3428,"activeCount":98},[],{"intervention":3430,"totalTrials":94,"cells":3431},"MK-1775 and carboplatin",{"EARLY_PHASE1":3432,"PHASE1":3434,"PHASE2":3436,"PHASE3":3448,"PHASE4":3450,"NA":3452},{"trials":3433,"activeCount":98},[],{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[3438],{"nctId":3439,"briefTitle":3440,"status":131,"phases":3441,"primaryCompletion":3442,"completion":3442,"start":3443,"enrollment":3444,"conditions":3445,"interventions":3447},"NCT01164995","Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer",[87],"2023-04","2010-07",24,[3446],"Epithelial Ovarian Cancer",[3430],{"trials":3449,"activeCount":98},[],{"trials":3451,"activeCount":98},[],{"trials":3453,"activeCount":98},[],{"intervention":3455,"totalTrials":94,"cells":3456},"Galunisertib",{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3471,"PHASE4":3473,"NA":3475},{"trials":3458,"activeCount":98},[],{"trials":3460,"activeCount":98},[],{"trials":3462,"activeCount":98},[3463],{"nctId":3464,"briefTitle":3465,"status":182,"phases":3466,"primaryCompletion":3467,"completion":3467,"start":3468,"enrollment":98,"conditions":3469,"interventions":3470},"NCT03470350","Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer",[86,87],"2020-06-01","2018-08-24",[2082],[3455],{"trials":3472,"activeCount":98},[],{"trials":3474,"activeCount":98},[],{"trials":3476,"activeCount":98},[],{"intervention":3478,"totalTrials":94,"cells":3479},"nivolumab and ipilimumab",{"EARLY_PHASE1":3480,"PHASE1":3482,"PHASE2":3484,"PHASE3":3495,"PHASE4":3497,"NA":3499},{"trials":3481,"activeCount":98},[],{"trials":3483,"activeCount":98},[],{"trials":3485,"activeCount":98},[3486],{"nctId":3487,"briefTitle":3488,"status":131,"phases":3489,"primaryCompletion":3490,"completion":1346,"start":3491,"enrollment":3492,"conditions":3493,"interventions":3494},"NCT03048474","Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma",[87],"2017-12","2016-09",36,[295],[3478],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[],{"intervention":188,"totalTrials":94,"cells":3502},{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3513,"PHASE4":3515,"NA":3517},{"trials":3504,"activeCount":98},[],{"trials":3506,"activeCount":98},[],{"trials":3508,"activeCount":98},[3509],{"nctId":180,"briefTitle":181,"status":182,"phases":3510,"primaryCompletion":184,"completion":184,"start":184,"enrollment":98,"conditions":3511,"interventions":3512},[87],[186],[121,163,188],{"trials":3514,"activeCount":98},[],{"trials":3516,"activeCount":98},[],{"trials":3518,"activeCount":98},[],{"intervention":3520,"totalTrials":94,"cells":3521},"Propranolol",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3538,"PHASE4":3540,"NA":3542},{"trials":3523,"activeCount":98},[],{"trials":3525,"activeCount":98},[],{"trials":3527,"activeCount":98},[3528],{"nctId":3529,"briefTitle":3530,"status":131,"phases":3531,"primaryCompletion":3532,"completion":3532,"start":3533,"enrollment":3534,"conditions":3535,"interventions":3537},"NCT04518124","Propranolol in Angiosarcoma",[87],"2023-10-30","2019-12-27",14,[3536],"Angiosarcoma",[3520],{"trials":3539,"activeCount":98},[],{"trials":3541,"activeCount":98},[],{"trials":3543,"activeCount":98},[],{"intervention":3545,"totalTrials":94,"cells":3546},"LY3200882",{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3551,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3548,"activeCount":98},[],{"trials":3550,"activeCount":98},[],{"trials":3552,"activeCount":98},[3553],{"nctId":3554,"briefTitle":3555,"status":182,"phases":3556,"primaryCompletion":221,"completion":221,"start":221,"enrollment":98,"conditions":3557,"interventions":3558},"NCT04031872","LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)",[86,87],[2082],[3545],{"trials":3560,"activeCount":98},[],{"trials":3562,"activeCount":98},[],{"trials":3564,"activeCount":98},[],{"intervention":3192,"totalTrials":94,"cells":3566},{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3577,"PHASE4":3579,"NA":3581},{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[],{"trials":3572,"activeCount":98},[3573],{"nctId":3182,"briefTitle":3183,"status":3184,"phases":3574,"primaryCompletion":3186,"completion":3187,"start":3188,"enrollment":3189,"conditions":3575,"interventions":3576},[87],[15],[3192,3193,3164,3164],{"trials":3578,"activeCount":98},[],{"trials":3580,"activeCount":98},[],{"trials":3582,"activeCount":98},[],{"intervention":3193,"totalTrials":94,"cells":3584},{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3589,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3586,"activeCount":98},[],{"trials":3588,"activeCount":98},[],{"trials":3590,"activeCount":98},[3591],{"nctId":3182,"briefTitle":3183,"status":3184,"phases":3592,"primaryCompletion":3186,"completion":3187,"start":3188,"enrollment":3189,"conditions":3593,"interventions":3594},[87],[15],[3192,3193,3164,3164],{"trials":3596,"activeCount":98},[],{"trials":3598,"activeCount":98},[],{"trials":3600,"activeCount":98},[],{"intervention":1337,"totalTrials":94,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3604,"activeCount":98},[],{"trials":3606,"activeCount":98},[],{"trials":3608,"activeCount":98},[3609],{"nctId":1330,"briefTitle":1331,"status":131,"phases":3610,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":16,"conditions":3611,"interventions":3612},[86,87],[21],[991,1337,1211],{"trials":3614,"activeCount":98},[],{"trials":3616,"activeCount":98},[],{"trials":3618,"activeCount":98},[],{"intervention":3620,"totalTrials":94,"cells":3621},"Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab",{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3639,"PHASE4":3641,"NA":3643},{"trials":3623,"activeCount":98},[],{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[3628],{"nctId":3629,"briefTitle":3630,"status":169,"phases":3631,"primaryCompletion":3632,"start":3633,"conditions":3634,"interventions":3637},"NCT01359397","Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer",[87],"2015-05","2011-03",[3635,3636],"Metastatic Gastric Cancer","Adenocarcinoma of the Gastro-oesophageal Junction",[3620,3638],"Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab",{"trials":3640,"activeCount":98},[],{"trials":3642,"activeCount":98},[],{"trials":3644,"activeCount":98},[],{"intervention":3638,"totalTrials":94,"cells":3646},{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3657,"PHASE4":3659,"NA":3661},{"trials":3648,"activeCount":98},[],{"trials":3650,"activeCount":98},[],{"trials":3652,"activeCount":98},[3653],{"nctId":3629,"briefTitle":3630,"status":169,"phases":3654,"primaryCompletion":3632,"start":3633,"conditions":3655,"interventions":3656},[87],[3635,3636],[3620,3638],{"trials":3658,"activeCount":98},[],{"trials":3660,"activeCount":98},[],{"trials":3662,"activeCount":98},[],{"intervention":913,"totalTrials":94,"cells":3664},{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3675,"PHASE4":3677,"NA":3679},{"trials":3666,"activeCount":98},[],{"trials":3668,"activeCount":98},[],{"trials":3670,"activeCount":98},[3671],{"nctId":904,"briefTitle":905,"status":131,"phases":3672,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":3673,"interventions":3674},[86,87],[645],[913,45,83],{"trials":3676,"activeCount":98},[],{"trials":3678,"activeCount":98},[],{"trials":3680,"activeCount":98},[],{"intervention":1353,"totalTrials":94,"cells":3682},{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3684,"activeCount":98},[],{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[3689],{"nctId":1343,"briefTitle":1344,"status":169,"phases":3690,"primaryCompletion":143,"completion":1346,"start":1347,"enrollment":1348,"conditions":3691,"interventions":3692},[86,87],[768,1350,1351,26],[974,1353,1211],{"trials":3694,"activeCount":98},[],{"trials":3696,"activeCount":98},[],{"trials":3698,"activeCount":98},[],{"intervention":3700,"totalTrials":94,"cells":3701},"TCR transduced T-cells",{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3719,"PHASE4":3721,"NA":3723},{"trials":3703,"activeCount":98},[],{"trials":3705,"activeCount":98},[],{"trials":3707,"activeCount":98},[3708],{"nctId":3709,"briefTitle":3710,"status":169,"phases":3711,"primaryCompletion":3712,"completion":3713,"start":3714,"enrollment":1252,"conditions":3715,"interventions":3718},"NCT02654821","Study With T-cel Receptor Gene Therapy in Metastatic Melanoma",[86,87],"2019-10","2020-01","2012-03",[3716,3717],"Stage IV Skin Melanoma","Eye; Melanoma",[3700],{"trials":3720,"activeCount":98},[],{"trials":3722,"activeCount":98},[],{"trials":3724,"activeCount":98},[],{"intervention":3726,"totalTrials":94,"cells":3727},"Arm A: Atezolizumab and Radiotherapy",{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3732,"PHASE3":3744,"PHASE4":3746,"NA":3748},{"trials":3729,"activeCount":98},[],{"trials":3731,"activeCount":98},[],{"trials":3733,"activeCount":98},[3734],{"nctId":3735,"briefTitle":3736,"status":131,"phases":3737,"primaryCompletion":3738,"completion":3739,"start":3740,"enrollment":9,"conditions":3741,"interventions":3742},"NCT03686332","PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study",[87],"2022-09-28","2023-09-15","2018-09-25",[1135],[3726,3743],"Arm B: Atezolizumab",{"trials":3745,"activeCount":98},[],{"trials":3747,"activeCount":98},[],{"trials":3749,"activeCount":98},[],{"intervention":3743,"totalTrials":94,"cells":3751},{"EARLY_PHASE1":3752,"PHASE1":3754,"PHASE2":3756,"PHASE3":3762,"PHASE4":3764,"NA":3766},{"trials":3753,"activeCount":98},[],{"trials":3755,"activeCount":98},[],{"trials":3757,"activeCount":98},[3758],{"nctId":3735,"briefTitle":3736,"status":131,"phases":3759,"primaryCompletion":3738,"completion":3739,"start":3740,"enrollment":9,"conditions":3760,"interventions":3761},[87],[1135],[3726,3743],{"trials":3763,"activeCount":98},[],{"trials":3765,"activeCount":98},[],{"trials":3767,"activeCount":98},[],{"intervention":1677,"totalTrials":94,"cells":3769},{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3771,"activeCount":98},[],{"trials":3773,"activeCount":98},[],{"trials":3775,"activeCount":98},[3776],{"nctId":1669,"briefTitle":1670,"status":131,"phases":3777,"primaryCompletion":1672,"completion":1673,"start":1674,"enrollment":16,"conditions":3778,"interventions":3779},[86,87],[21],[1677,1678],{"trials":3781,"activeCount":98},[],{"trials":3783,"activeCount":98},[],{"trials":3785,"activeCount":98},[],{"intervention":3787,"totalTrials":94,"cells":3788},"T-VEC",{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3793,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3790,"activeCount":98},[],{"trials":3792,"activeCount":98},[],{"trials":3794,"activeCount":98},[3795],{"nctId":3796,"briefTitle":3797,"status":131,"phases":3798,"primaryCompletion":3799,"completion":3800,"start":3801,"enrollment":3444,"conditions":3802,"interventions":3805},"NCT04330430","Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB\u002FC\u002FD-IV M1a) Melanoma with Injectable Disease",[87],"2023-04-09","2025-01-29","2020-09-08",[3803,3804],"Melanoma Stage III","Melanoma Stage IV",[3787],{"trials":3807,"activeCount":98},[],{"trials":3809,"activeCount":98},[],{"trials":3811,"activeCount":98},[],{"intervention":3813,"totalTrials":94,"cells":3814},"Vinorelbine Tartrate",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3830,"PHASE4":3832,"NA":3834},{"trials":3816,"activeCount":98},[],{"trials":3818,"activeCount":98},[],{"trials":3820,"activeCount":98},[3821],{"nctId":3822,"briefTitle":3823,"status":131,"phases":3824,"primaryCompletion":3825,"completion":3825,"start":3826,"enrollment":94,"conditions":3827,"interventions":3829},"NCT03482362","Vinorelbine in Advanced BRAF-like Colon Cancer",[87],"2020-03-17","2018-03-01",[3828],"Colon Cancer",[3813],{"trials":3831,"activeCount":98},[],{"trials":3833,"activeCount":98},[],{"trials":3835,"activeCount":98},[],{"intervention":3837,"totalTrials":94,"cells":3838},"Vorinostat",{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3854,"PHASE4":3856,"NA":3858},{"trials":3840,"activeCount":98},[],{"trials":3842,"activeCount":98},[],{"trials":3844,"activeCount":98},[3845],{"nctId":3846,"briefTitle":3847,"status":131,"phases":3848,"primaryCompletion":3849,"completion":3849,"start":3850,"enrollment":845,"conditions":3851,"interventions":3853},"NCT02836548","HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma",[86,87],"2023-11","2016-06",[31,3852],"Skin Neoplasms",[3837],{"trials":3855,"activeCount":98},[],{"trials":3857,"activeCount":98},[],{"trials":3859,"activeCount":98},[],{"intervention":3861,"totalTrials":94,"cells":3862},"paclitaxel, trastuzumab and carboplatin",{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3867,"PHASE3":3878,"PHASE4":3880,"NA":3882},{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[],{"trials":3868,"activeCount":98},[3869],{"nctId":3870,"briefTitle":3871,"status":131,"phases":3872,"primaryCompletion":3873,"completion":1396,"start":3874,"enrollment":3875,"conditions":3876,"interventions":3877},"NCT00768859","Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study",[87],"2011-08","2008-09",111,[15,370],[3861],{"trials":3879,"activeCount":98},[],{"trials":3881,"activeCount":98},[],{"trials":3883,"activeCount":98},[],{"intervention":3885,"totalTrials":94,"cells":3886},"Capecitabine, 5-fluorouracil",{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3899,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3888,"activeCount":98},[],{"trials":3890,"activeCount":98},[3891],{"nctId":3892,"briefTitle":3893,"status":131,"phases":3894,"primaryCompletion":3895,"completion":3895,"start":3000,"enrollment":3896,"conditions":3897,"interventions":3898},"NCT00838370","Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines",[86],"2011-10",22,[880],[3885],{"trials":3900,"activeCount":98},[],{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"intervention":3908,"totalTrials":94,"cells":3909},"177Lu-PSMA-617",{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3911,"activeCount":98},[],{"trials":3913,"activeCount":98},[3914],{"nctId":3915,"briefTitle":3916,"status":131,"phases":3917,"primaryCompletion":3918,"completion":3918,"start":3919,"enrollment":3534,"conditions":3920,"interventions":3922},"NCT05162573","EBRT + Lu-PSMA for N1M0 Prostate Cancer",[86],"2025-09-09","2021-12-20",[3921],"Prostatic Neoplasm",[3908],{"trials":3924,"activeCount":98},[],{"trials":3926,"activeCount":98},[],{"trials":3928,"activeCount":98},[],{"trials":3930,"activeCount":98},[],{"intervention":3932,"totalTrials":94,"cells":3933},"Infusion with ipilimumab 3 mg\u002Fkg q3wks",{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3947,"PHASE3":3949,"PHASE4":3951,"NA":3953},{"trials":3935,"activeCount":98},[],{"trials":3937,"activeCount":98},[3938],{"nctId":3939,"briefTitle":3940,"status":169,"phases":3941,"primaryCompletion":3942,"completion":829,"start":830,"enrollment":1204,"conditions":3943,"interventions":3945},"NCT02437279","Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients",[86],"2018-06-28",[3944],"Stage III Skin Melanoma",[3932,3946],"Infusion with nivolumab 1 mg\u002Fkg q3wks",{"trials":3948,"activeCount":98},[],{"trials":3950,"activeCount":98},[],{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[],{"intervention":3946,"totalTrials":94,"cells":3956},{"EARLY_PHASE1":3957,"PHASE1":3959,"PHASE2":3965,"PHASE3":3967,"PHASE4":3969,"NA":3971},{"trials":3958,"activeCount":98},[],{"trials":3960,"activeCount":98},[3961],{"nctId":3939,"briefTitle":3940,"status":169,"phases":3962,"primaryCompletion":3942,"completion":829,"start":830,"enrollment":1204,"conditions":3963,"interventions":3964},[86],[3944],[3932,3946],{"trials":3966,"activeCount":98},[],{"trials":3968,"activeCount":98},[],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[],{"intervention":3974,"totalTrials":94,"cells":3975},"oral docetaxel",{"EARLY_PHASE1":3976,"PHASE1":3978,"PHASE2":3990,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3977,"activeCount":98},[],{"trials":3979,"activeCount":98},[3980],{"nctId":3981,"briefTitle":3982,"status":153,"phases":3983,"primaryCompletion":3984,"completion":3985,"start":3491,"enrollment":3444,"conditions":3986,"interventions":3988},"NCT03066154","Oral Docetaxel (ModraDoc\u002Fr) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer",[86],"2022-02","2022-08",[3987],"Prostatic Neoplasms",[3974,3989],"androgen deprivation therapy",{"trials":3991,"activeCount":98},[],{"trials":3993,"activeCount":98},[],{"trials":3995,"activeCount":98},[],{"trials":3997,"activeCount":98},[],{"intervention":3989,"totalTrials":94,"cells":3999},{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4008,"PHASE3":4010,"PHASE4":4012,"NA":4014},{"trials":4001,"activeCount":98},[],{"trials":4003,"activeCount":98},[4004],{"nctId":3981,"briefTitle":3982,"status":153,"phases":4005,"primaryCompletion":3984,"completion":3985,"start":3491,"enrollment":3444,"conditions":4006,"interventions":4007},[86],[3987],[3974,3989],{"trials":4009,"activeCount":98},[],{"trials":4011,"activeCount":98},[],{"trials":4013,"activeCount":98},[],{"trials":4015,"activeCount":98},[],{"intervention":4017,"totalTrials":94,"cells":4018},"AZD1390 + radiotherapy",{"EARLY_PHASE1":4019,"PHASE1":4021,"PHASE2":4033,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4020,"activeCount":98},[],{"trials":4022,"activeCount":98},[4023],{"nctId":4024,"briefTitle":4025,"status":153,"phases":4026,"primaryCompletion":4027,"completion":4027,"start":4028,"enrollment":1252,"conditions":4029,"interventions":4031},"NCT05116254","Sarcomas and DDR-Inhibition; a Combined Modality Study",[86],"2025-12-09","2022-07-18",[4030],"Soft Tissue Sarcoma Adult",[4017,4032],"AZD1390 + durvlaumab + radiotherapy",{"trials":4034,"activeCount":98},[],{"trials":4036,"activeCount":98},[],{"trials":4038,"activeCount":98},[],{"trials":4040,"activeCount":98},[],{"intervention":4032,"totalTrials":94,"cells":4042},{"EARLY_PHASE1":4043,"PHASE1":4045,"PHASE2":4051,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4044,"activeCount":98},[],{"trials":4046,"activeCount":98},[4047],{"nctId":4024,"briefTitle":4025,"status":153,"phases":4048,"primaryCompletion":4027,"completion":4027,"start":4028,"enrollment":1252,"conditions":4049,"interventions":4050},[86],[4030],[4017,4032],{"trials":4052,"activeCount":98},[],{"trials":4054,"activeCount":98},[],{"trials":4056,"activeCount":98},[],{"trials":4058,"activeCount":98},[],{"intervention":4060,"totalTrials":94,"cells":4061},"carboplatin, olaparib",{"EARLY_PHASE1":4062,"PHASE1":4064,"PHASE2":4074,"PHASE3":4076,"PHASE4":4078,"NA":4080},{"trials":4063,"activeCount":98},[],{"trials":4065,"activeCount":98},[4066],{"nctId":4067,"briefTitle":4068,"status":131,"phases":4069,"primaryCompletion":4070,"completion":4070,"start":3632,"enrollment":1096,"conditions":4071,"interventions":4073},"NCT02418624","Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer",[86],"2019-01",[15,29,4072],"Advanced Cancer",[4060],{"trials":4075,"activeCount":98},[],{"trials":4077,"activeCount":98},[],{"trials":4079,"activeCount":98},[],{"trials":4081,"activeCount":98},[],{"intervention":4083,"totalTrials":94,"cells":4084},"ModraDoc001 10mg",{"EARLY_PHASE1":4085,"PHASE1":4087,"PHASE2":4101,"PHASE3":4103,"PHASE4":4105,"NA":4107},{"trials":4086,"activeCount":98},[],{"trials":4088,"activeCount":98},[4089],{"nctId":4090,"briefTitle":4091,"status":131,"phases":4092,"primaryCompletion":4093,"completion":4094,"start":4095,"enrollment":4096,"conditions":4097,"interventions":4098},"NCT01173913","Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir",[86],"2016-10-04","2017-01-26","2010-09",57,[960],[4083,4099,4100],"ModraDoc003 10mg tablets and ModraDoc004 10\u002F50 mg","ModraDoc006 10 mg",{"trials":4102,"activeCount":98},[],{"trials":4104,"activeCount":98},[],{"trials":4106,"activeCount":98},[],{"trials":4108,"activeCount":98},[],{"intervention":4099,"totalTrials":94,"cells":4110},{"EARLY_PHASE1":4111,"PHASE1":4113,"PHASE2":4119,"PHASE3":4121,"PHASE4":4123,"NA":4125},{"trials":4112,"activeCount":98},[],{"trials":4114,"activeCount":98},[4115],{"nctId":4090,"briefTitle":4091,"status":131,"phases":4116,"primaryCompletion":4093,"completion":4094,"start":4095,"enrollment":4096,"conditions":4117,"interventions":4118},[86],[960],[4083,4099,4100],{"trials":4120,"activeCount":98},[],{"trials":4122,"activeCount":98},[],{"trials":4124,"activeCount":98},[],{"trials":4126,"activeCount":98},[],{"intervention":4100,"totalTrials":94,"cells":4128},{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4137,"PHASE3":4139,"PHASE4":4141,"NA":4143},{"trials":4130,"activeCount":98},[],{"trials":4132,"activeCount":98},[4133],{"nctId":4090,"briefTitle":4091,"status":131,"phases":4134,"primaryCompletion":4093,"completion":4094,"start":4095,"enrollment":4096,"conditions":4135,"interventions":4136},[86],[960],[4083,4099,4100],{"trials":4138,"activeCount":98},[],{"trials":4140,"activeCount":98},[],{"trials":4142,"activeCount":98},[],{"trials":4144,"activeCount":98},[],{"intervention":4146,"totalTrials":94,"cells":4147},"RMC-4630",{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4164,"PHASE3":4166,"PHASE4":4168,"NA":4170},{"trials":4149,"activeCount":98},[],{"trials":4151,"activeCount":98},[4152],{"nctId":4153,"briefTitle":4154,"status":153,"phases":4155,"primaryCompletion":4156,"completion":4156,"start":4157,"enrollment":3444,"conditions":4158,"interventions":4162},"NCT04916236","Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers",[86],"2024-07-30","2022-03-31",[4159,21,4160,4161],"Pancreatic Cancer","Non-small Cell Lung Cancer","KRAS Mutation-Related Tumors",[4146,4163],"LY3214996",{"trials":4165,"activeCount":98},[],{"trials":4167,"activeCount":98},[],{"trials":4169,"activeCount":98},[],{"trials":4171,"activeCount":98},[],{"intervention":4163,"totalTrials":94,"cells":4173},{"EARLY_PHASE1":4174,"PHASE1":4176,"PHASE2":4182,"PHASE3":4184,"PHASE4":4186,"NA":4188},{"trials":4175,"activeCount":98},[],{"trials":4177,"activeCount":98},[4178],{"nctId":4153,"briefTitle":4154,"status":153,"phases":4179,"primaryCompletion":4156,"completion":4156,"start":4157,"enrollment":3444,"conditions":4180,"interventions":4181},[86],[4159,21,4160,4161],[4146,4163],{"trials":4183,"activeCount":98},[],{"trials":4185,"activeCount":98},[],{"trials":4187,"activeCount":98},[],{"trials":4189,"activeCount":98},[],{"intervention":4191,"totalTrials":94,"cells":4192},"carbplatin, cyclophophamide, atezolizumab",{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4214},{"trials":4194,"activeCount":98},[],{"trials":4196,"activeCount":98},[4197],{"nctId":4198,"briefTitle":4199,"status":131,"phases":4200,"primaryCompletion":4201,"completion":4202,"start":4203,"enrollment":1252,"conditions":4204,"interventions":4207},"NCT02914470","Carboplatin-cyclophosphamide Combined With Atezolizumab",[86],"2017-08","2021-10","2017-01",[15,4205,29,4206],"Cervix Cancer","Endometrial Cancer",[4191],{"trials":4209,"activeCount":98},[],{"trials":4211,"activeCount":98},[],{"trials":4213,"activeCount":98},[],{"trials":4215,"activeCount":98},[],{"intervention":4217,"totalTrials":94,"cells":4218},"New Pazopanib formulation",{"EARLY_PHASE1":4219,"PHASE1":4230,"PHASE2":4232,"PHASE3":4234,"PHASE4":4236,"NA":4238},{"trials":4220,"activeCount":98},[4221],{"nctId":4222,"briefTitle":4223,"status":131,"phases":4224,"primaryCompletion":4225,"completion":4225,"start":4226,"enrollment":1252,"conditions":4227,"interventions":4229},"NCT02810756","Study With Improved Solubility Pazopanib",[85],"2017-08-28","2016-09-15",[4228],"Pharmacokinetics of Pazopanib",[4217],{"trials":4231,"activeCount":98},[],{"trials":4233,"activeCount":98},[],{"trials":4235,"activeCount":98},[],{"trials":4237,"activeCount":98},[],{"trials":4239,"activeCount":98},[],{"intervention":4241,"totalTrials":94,"cells":4242},"Dexamphetamine",{"EARLY_PHASE1":4243,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4260,"NA":4262},{"trials":4244,"activeCount":98},[4245],{"nctId":4246,"briefTitle":4247,"status":131,"phases":4248,"primaryCompletion":4249,"completion":4249,"start":4250,"enrollment":1252,"conditions":4251,"interventions":4253},"NCT02768441","Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots",[85],"2017-06-01","2016-11-01",[4252],"Cocaine Addiction",[4241],{"trials":4255,"activeCount":98},[],{"trials":4257,"activeCount":98},[],{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[],{"trials":4263,"activeCount":98},[],{"intervention":4265,"totalTrials":279,"cells":4266},"Fluoropyrimidine",{"EARLY_PHASE1":4267,"PHASE1":4269,"PHASE2":4271,"PHASE3":4273,"PHASE4":4275,"NA":4277},{"trials":4268,"activeCount":98},[],{"trials":4270,"activeCount":98},[],{"trials":4272,"activeCount":98},[],{"trials":4274,"activeCount":98},[],{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[4279,4288],{"nctId":4280,"briefTitle":4281,"status":169,"phases":4282,"primaryCompletion":4283,"completion":4283,"start":4284,"enrollment":4285,"conditions":4286,"interventions":4287},"NCT04194957","Improving the Safety of Fluoropyrimidine-based Chemotherapy",[90],"2021-01","2020-01-15",1440,[880],[4265,4265,4265],{"nctId":4289,"briefTitle":4290,"status":131,"phases":4291,"primaryCompletion":4292,"completion":4293,"start":4294,"enrollment":4295,"conditions":4296,"interventions":4297},"NCT02324452","Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines",[90],"2018-01","2018-03","2015-03",1103,[880],[4265],{"intervention":4299,"totalTrials":94,"cells":4300},"Radium-223 dichloride",{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4307,"PHASE4":4309,"NA":4311},{"trials":4302,"activeCount":98},[],{"trials":4304,"activeCount":98},[],{"trials":4306,"activeCount":98},[],{"trials":4308,"activeCount":98},[],{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[4313],{"nctId":4314,"briefTitle":4315,"status":131,"phases":4316,"primaryCompletion":4317,"completion":3826,"start":4318,"enrollment":4319,"conditions":4320,"interventions":4322},"NCT03223597","Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223",[],"2015-02-01","2015-01-17",300,[2908,4321],"Bone Metastases",[4299],{"intervention":4324,"totalTrials":94,"cells":4325},"Midazolam",{"EARLY_PHASE1":4326,"PHASE1":4328,"PHASE2":4330,"PHASE3":4332,"PHASE4":4334,"NA":4336},{"trials":4327,"activeCount":98},[],{"trials":4329,"activeCount":98},[],{"trials":4331,"activeCount":98},[],{"trials":4333,"activeCount":98},[],{"trials":4335,"activeCount":98},[],{"trials":4337,"activeCount":98},[4338],{"nctId":4339,"briefTitle":4340,"status":131,"phases":4341,"primaryCompletion":4342,"completion":4342,"start":4343,"enrollment":157,"conditions":4344,"interventions":4346},"NCT05518799","CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours",[90],"2022-12-02","2021-04-22",[18,4345],"Solid Tumor, Adult",[4324],{"intervention":4348,"totalTrials":94,"cells":4349},"Liquid",{"EARLY_PHASE1":4350,"PHASE1":4352,"PHASE2":4354,"PHASE3":4356,"PHASE4":4358,"NA":4360},{"trials":4351,"activeCount":98},[],{"trials":4353,"activeCount":98},[],{"trials":4355,"activeCount":98},[],{"trials":4357,"activeCount":98},[],{"trials":4359,"activeCount":98},[],{"trials":4361,"activeCount":98},[4362],{"nctId":4363,"briefTitle":4364,"status":169,"phases":4365,"primaryCompletion":4366,"completion":1346,"start":3850,"enrollment":4367,"conditions":4368,"interventions":4369},"NCT02894853","Lung Cancer Early Molecular Assessment Trial",[],"2019-06",1297,[26],[4348],{"intervention":4371,"totalTrials":94,"cells":4372},"Morphine",{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4377,"PHASE3":4379,"PHASE4":4381,"NA":4383},{"trials":4374,"activeCount":98},[],{"trials":4376,"activeCount":98},[],{"trials":4378,"activeCount":98},[],{"trials":4380,"activeCount":98},[],{"trials":4382,"activeCount":98},[],{"trials":4384,"activeCount":98},[4385],{"nctId":4386,"briefTitle":4387,"status":169,"phases":4388,"primaryCompletion":2957,"completion":2957,"start":4389,"enrollment":328,"conditions":4390,"interventions":4392},"NCT05590559","Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block in Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction - a Non-inferiority Trial",[90],"2021-06-01",[4391],"Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction",[4371]]